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ABSTRACT 
 
Respiratory syncytial virus (RSV) is the major causative agent of acute lower 
respiratory tract infections in infants and young children. Unfortunately, there are no 
licensed RSV vaccines available, and the few treatment options for high-risk individuals 
are either extremely costly or cause severe side effects and toxicity. Thus, the 
development of effective vaccines and therapeutic interventions against RSV is a 
preeminent public health priority.  
Pneumonia virus of mice (PVM) causes similar clinical symptoms and disease in 
mice to those observed in RSV-infected patients, and therefore is used as a model for 
pathogenesis studies. Lethal PVM infection (i.e. 3000 pfu) in Balb/c mice is 
characterized by 20% weight loss in total body weight, rough coats, abnormal posture, 
nasal discharge, and difficulty breathing due to neutrophilia, edema and alveolitis in the 
lower airways. Also, these mice will succumb to the infection between days 6 and 7 p.i. 
Immunomodulation mediated by a novel formulation composed of the toll-like 
receptor 3 agonist poly I:C, an innate defense regulator peptide and a polyphosphazene 
(i.e. P-I-P) was first assessed in healthy adult Balb/c mice. Subsequently, the protective 
potential of P-I-P was further investigated in the context of a lethal PVM infection. P-I-P 
induced highest mRNA and protein expression of chemokines and cytokines in the lung 
milieu between 6 and 24 hr post-treatment. In addition, a single dose of P-I-P protected 
adult mice against PVM when given 24 hr prior to challenge. These animals displayed 
minimal body weight changes, no clinical disease, 100% survival, as well as reduced lung 
virus titers and pathology. P-I-P pre-treatment induced early mRNA and protein 
expression of key chemokine and cytokines, and decreased neutrophil and eosinophil 
numbers in the lungs, resulting in an overall modulation of the delayed exacerbated 
nature of PVM disease without short-term side effects. It was determined that the 
protective effects of P-I-P prophylaxis were maintained if administered up to 3 days prior 
to lethal PVM infection. On day 14 post-infection, P-I-P-treated survivor mice were 
confirmed to be PVM-free. These results demonstrate the capacity of this formulation to 
prevent PVM and possibly other viral respiratory infections. 
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1. INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Respiratory Syncytial Virus: Disease burden and epidemiology. 
 
Respiratory syncytial virus (RSV) is an enveloped, negative-sense single-stranded 
RNA virus, genus Pneumovirus of the Paramyxoviridae family. RSV disease was first 
documented in 1956, when an outbreak of severe coryza illness was reported in a colony 
of chimpanzees [1, 2].  The recovered agent responsible for the clinical symptoms 
observed in these animals was initially called “chimpanzee coryza agent” (CAA).  
Shortly after, the same virus was isolated from respiratory secretions of infants and young 
children with bronchiolitis and pneumonia [2, 3]. It was suggested that CAA was a virus 
of human origin, which could have been transmitted by the laboratory personnel in 
charge of handling the chimpanzees. In 1957, CAA was renamed “respiratory syncytial 
virus” as this agent had tissue tropism for cells of the respiratory tract and infection of the 
airway epithelium lead to syncytia formation [4]. 
Since its discovery in the mid-1950s, RSV is considered the most common cause of 
bronchiolitis and pneumonia in infants and young children. Global RSV disease accounts 
for approximately 34 million infections and 175,000 deaths each year [1, 5]. RSV exists 
as a single serotype with two major antigenic groups, namely A and B. During yearly 
epidemics, it has been observed that both subtypes tend to co-circulate within a given 
season. However, one of either genotype usually predominates [6, 7]. RSV-A and B 
subtypes mostly differ in sequences and epitopes of the attachment glycoprotein [1, 6]. It 
is thought that these antigenic variances might contribute to differences in infection and 
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disease susceptibility [7]. Several groups demonstrated that group A RSV was associated 
with worsened symptoms and enhanced clinical severity than those caused by the RSV-B 
subtype [1, 7]. However, some studies yielded controversial results suggesting that either 
subgroup was equally as pathogenic as the other. Thus, it remains unclear whether RSV 
strain differences play a role in disease severity [1, 7]. RSV circulates year-round within 
communities. In temperate regions, outbreaks are routinely reported during the fall, 
winter, and spring months, while in tropical climates highest incidence occurs during the 
rainy season [1, 6, 8]. Virus transmission occurs most commonly through direct contact 
with infected individuals and their secretions, via large particle droplets and/or fomites 
[1, 9]. Due to the extremely infectious nature of the virus, it is estimated that most 
children become infected with RSV by the age of two [1, 6]. Reinfections can occur 
repeatedly throughout life, often with mild upper respiratory tract (URT) symptoms in 
most healthy older children and adults [9-11]. Pre-term babies, newborn infants between 
2 and 4 months of age, immunocompromised individuals, and the elderly are at highest 
risk of developing severe RSV disease [9, 12]. In these populations, the virus can infect 
the lower respiratory tract (LRT), often leading to hospitalizations and in worst cases 
death [13].   
In the USA, the average RSV hospitalization rate for infants is estimated to be 26 per 
1,000, and for children between the ages of 1 to 5 is 1.8 per 1,000 [14]. Similar numbers 
were also reported in other developed nations, with highest hospitalization rates among 
infants and young children less than 5 years of age [15, 16]. In contrast to influenza- and 
parainfluenza virus (PIV)-induced hospitalization, RSV was responsible for 3 times 
higher rates among children, and 6 to 8 times greater in infants [1]. RSV-associated 
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mortality is rare in developed countries. In the USA, it is estimated that no more than 500 
fatal cases occur each year [17]. Death related to RSV infections during the winter season 
in the Netherlands is usually not observed among patients 1 to 18 years old [18]. Elderly 
patients are also at an increased risk of developing severe RSV disease, with 
hospitalization rates ranging from 14,000 to 62,000 per year in the USA [19]. Underlying 
conditions such as congestive heart failure and chronic lung disease are major 
contributing factors for high rates of hospitalization among the elderly [1]. In this 
population, RSV infections were responsible for 10.6% of hospitalizations for 
pneumonia, 11.4% for obstructive pulmonary disease, and 7.2% for asthma [20]. 
Mortality rates are also elevated in these patients. In the Netherlands, individuals 65 years 
of age and older have higher death rates during winter months than infants and young 
children [18].  
There is a poor understanding of RSV burden in the developing world. Existing data 
denote that the virus accounts for a high incidence of acute lower respiratory infections 
(ALRIs) in young children and infants [21]. A study conducted in 2005 estimated that 
RSV-associated disease in developing nations occurred at greater than twice the rate as 
compared to developed countries. Furthermore, 99% of all RSV-related deaths were 
reported in these countries [1, 21]. Lower diagnostic potential, restricted access to 
healthcare, and high hospitalization costs are several factors limiting studies on RSV 
incidence in developing countries [21, 22]. Thus, available data describing RSV disease 
burden in these communities are likely to be an underestimate of the true nature of this 
infection [1, 21].  	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1.2 Treatments available against RSV disease. 
 
Despite the significant public health burden of RSV in the world, there are no 
licensed vaccines available to date. In the 1960s, a vaccine candidate consisting of 
formalin-inactivated RSV (FI-RSV) in combination with alum was given intramuscularly 
to infants and young children [1, 5]. Unfortunately, this vaccine failed at inducing 
protective immune responses in these populations. Instead, subjects were primed to 
develop exacerbated disease upon exposure to subsequent natural RSV infections [1]. 
Also, FI-RSV vaccinated individuals displayed higher rates of hospitalizations and deaths 
than control infants vaccinated with an inactivated PIV-3 vaccine [5, 9, 23]. The failure 
of this vaccine candidate was mainly attributed to the generation of strong Th2-biased 
responses, high influx of lymphocytes, eosinophils, and neutrophils into the LRT, low 
avidity and non-neutralizing antibodies, poor toll-like receptor (TLR) activation, and 
minimal priming of CD8+ cytotoxic T cells in vivo [5, 9, 10].  
The management of patients with RSV bronchiolitis is primarily supportive in nature 
[11]. Treatment options consist of respiratory support with supplemental oxygen and 
mechanical ventilation, intravenous fluids, nasal suction, as well as the administration of 
bronchodilators and corticosteroids [1, 6]. Oxygen therapies are routinely used when 
oxygen saturation levels in the blood are below 90% [1]. Mechanical ventilators are often 
required when respiratory failure is observed, especially in high-risk patients such as 
infants and the immunocompromised [1]. The effectiveness of bronchodilator and 
corticosteroid treatments is controversial [1, 6, 24]. The latter therapy is often used when 
the lower airways are fully obstructed, resulting in difficulty breathing and wheezing. 
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There is evidence suggesting that administration of albuterol in patients with RSV-
induced respiratory failure did not much improve lung function and disease outcome 
[25]. Similarly, several human trials lead to the conclusion that neither nebulized nor 
intravenous delivery of corticosteroids was effective at shortening the length of 
hospitalization among infants with RSV bronchiolitis [26]. 
 
1.2.1 Palivizumab 
 
Several research groups conducting studies in cotton rats and humans demonstrated 
that passive transfer of immunoglobulins is a suitable approach to protect high-risk 
individuals from RSV disease [27]. It was found that convalescent sera from patients who 
previously had RSV did not contain sufficient RSV-specific neutralizing antibody levels 
to provide protection [27]. Thus, a high-titered intravenous immunoglobulin was created 
as a solution to this problem. RSV-IVIG (RespiGam; MedImmune, Inc., Gaithersburg, 
MD) was developed in 1996 as the first prophylactic agent against RSV infections in 
high-risk infants [1, 27]. This novel immunoglobulin consisted of pooled sera from 
individuals with high RSV-specific neutralizing antibody titers [1]. It was shown that 
RSV-IVIG reduced the rates of RSV-associated LRTIs in high-risk infants and young 
children [28]. However, RSV-IVIG prophylaxis in infants with congenital heart disease 
was linked to fluid overload due to large infusion volumes, oxygen desaturation and fever 
[28]. Thus, the use of RSV-IVIG in this population is contraindicated [27]. As a result of 
the several disadvantages posed by this approach, a novel monoclonal anti-RSV 
neutralizing antibody was developed [29]. Johnson et al. described the effectiveness of 
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the MEDI-493 antibody, currently known as palivizumab, both in vitro and in vivo [29]. 
It was demonstrated that MEDI-493 successfully neutralizes RSV-A and -B infections in 
human epithelial type 2 (HEp-2) cells [27, 29]. In addition, MEDI-493 prophylaxis in 
cotton rats completely eliminated virus replication without interfering with the 
development of protective responses [27, 29].  
Palivizumab (Synagis, MedImmune Vaccines, Inc., Gaithersburg, MD) is a 
humanized monoclonal antibody directed against the fusion (F) protein of RSV [1, 30]. In 
1998, the US Food and Drug Administration (FDA) approved palivizumab to be used for 
the prophylaxis of high-risk infants and young children. This antibody is routinely 
administered as an intramuscular injection, and given as a single dose of 15 mg/kg every 
30 days for a 5-month period [1, 6, 30]. Current guidelines recommend infants born at or 
before 32 weeks gestation, and currently age 6 or younger to receive palivizumab 
prophylactic therapy at the start of the local RSV season [1, 6, 30]. Two major human 
trials were conducted to assess the efficacy of palivizumab in high-risk pediatric patients 
[1]. It was concluded that the use of this antibody for prophylaxis was associated with a 
significant reduction in RSV-related hospitalization rates [31, 32]. Unlike RSV-IVIG, 
palivizumab did not cause any adverse effects in children with congenital heart disease 
[32].  
Unfortunately, the extremely high cost and administration logistics of palivizumab 
limit its use to patients in the developing world [1, 9, 11]. Currently, the average cost of a 
100 mg vial of palivizumab is $2,962 USD in the USA, and $1,505 CAD in Canada [33]. 
Several groups concluded that palivizumab prophylaxis in high-risk infants was not a 
cost-effective strategy to prevent RSV infections in this population [1, 34]. In addition, 
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patients must comply to follow a full course of palivizumab prophylaxis in order to reach 
sufficient levels of protective serum anti-RSV antibodies [1]. It is worth mentioning that 
palivizumab is certainly not a cure for RSV. According to several studies, palivizumab is 
most effective as a prophylactic agent, and not when used therapeutically [27]. This 
means that patients who already have an established RSV infection would not benefit 
from palivizumab therapy. While the use of palivizumab for prophylaxis has been 
successful at preventing RSV bronchiolitis in high-risk infants, it is still a non-sustainable 
approach to limit RSV infections and transmission within a community. 
 
1.2.2 Ribavirin 
 
Ribavirin (Virazole, Valeant Pharmaceuticals International, Aliso Viejo, CA), an 
FDA-approved broad-spectrum nucleoside analogue, is utilized to treat severe RSV 
bronchiolitis in high-risk infants and young children [1, 6, 24, 35]. It has been shown that 
ribavirin is also effective in vitro against measles virus, parainfluenza virus, adenovirus, 
hepatitis C virus and others [1, 35-37]. This antiviral drug does not affect the initial steps 
of a viral infection, such as attachment, penetration and uncoating [37]. Ribavirin acts 
primarily by inhibiting viral replication and transcription during the active growth phase 
[1, 36]. Nonetheless, its complete mechanism of action is yet to be elucidated.   
Ribavirin is most commonly administered as an aerosolized formulation, but it can 
also be given through intravenous or oral routes [1]. The typical dose of this agent is 20 
mg/ml, administered continuously for 12-18 hours over a period of 3-7 days [1, 35]. 
Ribavirin is usually delivered using a small particle aerosol generator model-2 (SPAG-2) 
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via a face mask inside an oxyhood or tent [35]. It has been demonstrated in several rodent 
models that ribavirin is a teratogenic substance [1, 24, 35, 37]. Therefore, this drug is 
contraindicated in pregnant women [1, 35]. Aerosolized ribavirin is also known to cause 
fatigue, nausea, headache, and anorexia [1]. In patients with chronic obstructive 
pulmonary disease (COPD) or asthma, ribavirin treatment has been correlated with an 
aggravation of respiratory function [1, 37]. Intravenous delivery of ribavirin is reserved 
for patients with poor lung penetration due to consolidative pneumonia [1]. On the other 
hand, oral ribavirin is much easier to administer but it has reduced bioavailability in vivo 
compared to aerosolized ribavirin [1]. Hemolytic anemia, nausea and leukopenia are 
several adverse effects associated with these two treatment routes [1, 37]. Ribavirin is 
also contraindicated in patients with a history of psychiatric disorders and severe 
depression as it can cause altered mental status [37].  
Although ribavirin treatment is effective at limiting viral transcription both in vitro 
and in vivo, consistent evidence supporting a direct benefit of the drug at reducing 
hospitalization rates and ameliorating disease outcomes in patients with severe RSV 
bronchiolitis is lacking [1, 12, 24, 36]. It has been suggested that the presence or absence 
of live virions in the respiratory tract does not affect the severity and progression of RSV-
induced inflammation [24]. Ventre and Randolph demonstrated that ribavirin therapy did 
not cause any significant improvement in mortality, length of hospitalization or 
ventilation in pediatric populations [38]. Thus, the American Academy of Pediatrics 
(AAP) does not recommend the routine use of this antiviral in such patients [1, 6]. 
Nevertheless, a combination of ribavirin and immunoglobulin (i.e. palivizumab) is 
commonly used in Hematopoietic Stem Cell Transplant (HSCT) recipients to treat RSV 
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bronchiolitis [35, 39]. Altogether, ribavirin treatment alone is not sufficient to treat RSV 
disease. Due to its high cost and all the potential side effects that can occur, this strategy 
is not the most suitable to implement in vulnerable populations like infants and young 
children.  
 
1.3 Factors involved in pathogenesis of RSV infection. 
 
RSV disease manifestations can range from mild rhinitis to severe bronchiolitis and 
pneumonia [1]. Primary RSV infections are characterized by high virus titers and delayed 
disease manifestations [40]. In individuals predisposed to enhanced RSV disease, a 
reduction in virus replication and rapid viral clearance is observed [40]. However, 
inflammatory responses tend to be exacerbated and often lead to immunopathology [40]. 
Certainly, clinical outcomes caused by RSV infections are multifactorial, which can be 
attributed to several host factors like genetics, age, premature birth, immunosuppression, 
underlying conditions, and others [1, 41]. RSV infections in vivo are mostly restricted to 
the superficial cells of the respiratory epithelium [1, 35, 42]. In the lower respiratory 
tract, RSV primarily targets ciliated cells of the small bronchioles and pneumocytes of 
the alveoli [42]. Severe RSV bronchiolitis shares similar pathology to influenza virus-, 
PIV-, and adenovirus-mediated bronchiolitis [40]. RSV replication in the LRT leads to 
edema by inducing necrosis of epithelial cells (ECs), high mucous production, and 
increased accumulation of leukocytes into the site of infection [35, 40, 42]. Thus, the 
small airways become obstructed resulting in patchy atelectasis and emphysema [35, 40]. 
Syncytia formation is not commonly observed in vivo, but is likely to occur in 
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immunocompromised patients [42]. A thorough understanding of the complex nature of 
RSV pathogenesis is pivotal for the development of successful vaccines and therapeutic 
interventions. 
 
1.3.1 Innate Immune System. 
 
The innate immune system acts as the first line of defense to ensure optimal 
pathogen control and survival of the host. In the context of RSV pathogenesis, the virus 
initiates its life cycle by primarily infecting the respiratory epithelium [1, 43, 44]. 
Resident macrophages of the lung milieu are also considered a major target for RSV 
infection within the tissue [41, 44, 45]. Following cellular attachment and entry, the virus 
and its pathogen-associated molecular patterns (PAMPs) are detected by several pattern 
recognition receptors (PRRs) located throughout the infected cell [1, 41, 43, 46]. Several 
PRRs involved in RSV pathogenesis are TLRs, nucleotide-binding oligomerization 
domain-like receptors (NLRs), and retinoic acid-inducible gene-I-like receptors (RLRs) 
[1, 41]. During replication, RSV is able to produce both single- and double-stranded 
RNA intermediates [47]. Out of all the PRRs present in the cell, TLRs have been the 
most studied in the context of RSV. For instance, TLR2, TLR3, TLR4 and TLR7 are 
known to be involved in the initial recognition of RSV by infected cells [1, 8]. As a result 
of this interaction, an array of signaling cascades are induced, leading to the production 
of both protective and pathological immune responses in the airways [1]. RSV infection 
activates the nuclear factor-kappaB (NF-κB) pathway, leading to the production of 
chemokine and cytokine proteins [40, 41, 47]. In addition, TLR signaling also leads to the 
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production of interferon (IFN-) α/β via IFN-regulatory factor 3 (IRF3) and IRF7 [40, 43, 
46]. Similarly, RSV infection also leads to the rapid induction and increased expression 
of the retinoic acid-inducible gene I (RIG-I) in the cell cytoplasm [1, 48]. The 
engagement of this RLR with viral RNA results in the activation of NF-κB and IRF3, 
mediating the induction of both type I and type III IFNs [1, 49]. Several groups have 
demonstrated that RIG-I is indeed the major RLR contributing to the IFN response at the 
level of innate immunity [1, 48, 50].  
 It has been found that during RSV infection, ECs and macrophages produce high 
amounts of cytokines and chemokines including IL-8 (CXCL1/KC in mice), CXCL10 
(IP-10), CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1b), CCL5 (RANTES), IL-6, 
TNF-α, CXCL2 (MIP-2), and IL-1α/β [1, 40, 41, 51-54]. Similarly, elevated levels of 
such factors have been detected in respiratory secretions of hospitalized pediatric patients 
with RSV bronchiolitis [1, 51, 55]. The presence of these molecules within the lung 
milieu increases vascular permeability, leading to the selective recruitment and activation 
of different cell subsets into the tissue [8].  
In the context of RSV infection, neutrophils, macrophages, eosinophils, and 
natural killer (NK) cells are the main innate immune cells involved in host defense and 
disease pathogenesis [1, 8, 41]. Neutrophils are the predominant innate immune cell 
present in the airways during severe RSV disease. According to a study of RSV 
bronchiolitis in pediatric patients, neutrophils constituted 93% of the cells in the URT and 
76% in the LRT [8, 41, 51, 56]. Neutrophil chemotaxis is highly dependent on IL-8 [8]. It 
has been shown that nasal lavages of infants with RSV bronchiolitis contain high 
concentrations of IL-8 [41, 57]. Thus, the upregulation of this chemokine is associated 
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with RSV disease severity [8, 51]. While neutrophils are needed to mediate virus 
clearance at the level of the innate immune system, elevated neutrophil counts often 
promote RSV-induced immunopathology and tissue damage [41, 51]. This is explained 
by their ability to secrete chemokines and pro-inflammatory cytokines that could possibly 
amplify the existing inflammatory response in the airways [51]. Eosinophils have also 
been involved in severe RSV disease. In one study, higher concentrations of eosinophilic 
cationic protein (ECP) were found in nasopharyngeal secretions of children with RSV 
bronchiolitis [51, 58]. The research group concluded that eosinophil degranulation 
products might play a role in the development of severe RSV disease in the LRT [58]. 
Despite these findings, researchers failed to detect an increase in eosinophil numbers in 
pulmonary lavages of RSV-infected children [8, 41, 51, 58]. NK cells are innate immune 
cells that play a pivotal role in the control of viral infections. These cells possess high 
cytotoxic activity, and are mainly activated by IFN-β, IL-12 and TNF-α [8]. The exact 
contribution of NK cells to RSV pathogenesis is yet to be elucidated [8]. Nonetheless, 
NK cells are one of the earliest cells to infiltrate the lungs during RSV infections, and are 
responsible for most of the early IFN-γ production in the lung [8, 59]. Weerd et al. 
demonstrated that hospitalized children with RSV bronchiolitis had lower NK cell counts 
in the blood than control patients [60]. The group concluded that this decrease in cell 
numbers corresponded to increased recruitment of these peripheral cells into the 
respiratory tract [8, 60].  
Viral infection of the airways results in the production of type I IFNs. These anti-
viral molecules bind to the IFN-α/β receptor (IFNAR) on the cell surface, and signal 
through the Janus-activated kinase (JAK)/signal transducer and activator of transcription 
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(STAT) pathway [1, 43]. Subsequently, the nuclear translocation of a complex composed 
of STAT-1, STAT-2 and IFN regulatory factor 9 (IRF9) leads to the expression of several 
IFN-stimulated genes (ISGs) that contribute to the anti-viral response [43]. Interestingly, 
RSV has developed ways to counteract the host’s innate immune responses. 
Nonstructural protein 1 (NS1) and 2 (NS2) of most paramyxoviruses are known to inhibit 
type I IFN production and signaling in vivo [1, 40]. These two proteins decrease STAT-2 
signaling cascade by targeting this transcription factor for degradation [43, 61]. In 
addition, NS1 and NS2 proteins prevent type I IFN synthesis by blocking IRF3 and TNF 
receptor-associated factor 3	   (TRAF3) signaling cascades [1, 62]. It has been 
demonstrated that STAT-1 and -2 knockout mice experience severe inflammation and 
increased Th2-type immune responses in the lungs during RSV infection [43, 63]. Thus, 
weakened type I IFN production and signaling might be a major factor contributing to 
severe RSV disease.  
 
1.3.2 Adaptive Immune System. 
 
While primary RSV infection successfully activates the host’s adaptive immune 
system, protective immunity is often weak in nature and short-lived [1, 42]. This is 
consistent with the notion that humans experience multiple RSV reinfections throughout 
their lifetime. Nevertheless, the appropriate induction of adaptive immune responses has 
been shown to be a critical factor involved in optimal control of RSV disease in humans 
[41].   
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Regarding the humoral response following RSV infection in humans, there is an 
induction of both IgA in the URT and IgG antibodies in the serum [1, 41]. A long-lasting 
induction of secretory IgA is of importance as it confers protection to the URT [42]. This 
in turn can prevent the virus from reaching into the LRT of the individual and causing a 
more severe disease outcome. In contrast, serum IgG plays a major role in protecting the 
LRT as this antibody can access this compartment more readily than the URT [42]. 
Maternal neutralizing anti-RSV antibodies can cross the placenta during pregnancy and 
provide newborns and infants with a temporary means of protection against the virus 
earlier on in life [8, 42]. However, these immunoglobulins wane quite rapidly after 
infection [41]. There is evidence suggesting that most adults infected with RSV within 1 
year of initial exposure experience a 4-fold decrease in neutralizing anti-RSV IgG titers 
[1]. Thus, the short-duration of the humoral response against RSV can explain why 
periodic reinfections tend to occur throughout life [1]. 
The role of cell-mediated immune responses in the context of RSV pathogenesis 
has been thoroughly investigated throughout the years. The nature of the T cell response 
following infection depends on the initial recognition of viral antigens by lung-resident 
dendritic cells (DCs) [41]. After engulfment of such antigens, cellular maturation occurs 
and DCs migrate into the lung draining lymph nodes where antigen presentation to naïve 
T cells takes place [1]. The nature of this event can have a major effect on the type of 
effector T cell response that is mounted against the virus. It has been concluded that T 
cell responses can mediate the effective clearance of the virus during primary infection 
[1]. Children with T cell immunodeficiencies experience longer periods of virus shedding 
and worsening of symptoms [1, 8]. According to a number of studies in mice, Th1 
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polarization of CD4+ T cells is required for effective virus control and elimination [42].  
The production and secretion of IFN-γ by these cells stimulates CD8+ T cells to become 
cytotoxic and direct the specific destruction of RSV-infected cells [41-43]. In addition, 
IFN-γ can enhance phagocytic activity in macrophages leading to improved clearance of 
cellular debris within the tissue [43].  It was demonstrated that mice ablated from CD8+ T 
cells prior to RSV infection display an overall delay in virus clearance [64]. Conversely, 
uncontrolled T-cell responses can also contribute significantly to exacerbating disease 
immunopathology [42]. Depletion of CD4+ and CD8+ T cells in vivo resulted in persistent 
virus replication with no remarkable signs of disease [64]. This supports the notion that 
the strength of the immune response to the virus, and not the virus itself, may enhance 
disease severity [8, 40]. The contribution of regulatory T cells (Tregs) to RSV disease 
pathogenesis has been recently studied. Treg depletion in mice prior to RSV infection 
resulted in increased disease severity that correlated with elevated levels of IL-6 and 
higher leukocyte recruitment into the airways [65]. It has been suggested that Tregs are 
important in limiting RSV-induced immunopathology, as their depletion did not have a 
major effect on virus clearance [66].       
RSV-mediated pulmonary pathology is characterized by mucus overproduction 
and airway hyperreactivity [1]. It appears that CD4+ T cells of the Th2 phenotype may be 
responsible for such clinical signs due to the secretion of Th2-type cytokines like IL-4, 
IL-5 and IL-13 [1]. Additional reasons supporting the role of these cells in RSV 
pathogenesis include the general tendency of the neonatal immune system to mount Th2-
biased responses, and the similarities between RSV-induced pathological lesions and the 
asthma phenotype (i.e. high IgG1 and IgE antibody titers, eosinophil accumulation and 
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degranulation in the lower airways) [40, 42]. It has been reported that there is a strong 
association between elevated mRNA expression and protein concentration of Th2 
cytokines in nasal secretions and stimulated peripheral blood mononuclear cells (PBMCs) 
and disease severity in pediatric patients [42]. While RSV infection in humans is able to 
induce both Th1 and Th2 responses, disease severity is highly dependent on host factors 
that are likely to affect the overall balance of the immune response. Ultimately, a better 
understanding on how age and host’s genetics can shape RSV disease is needed in order 
to fully comprehend the complex nature of the virus.  
 
1.4 Pneumoviruses as animal models of RSV disease. 
 
Despite numerous attempts to fully understand the nature of RSV pathogenesis in 
humans, research involving subjects of different age groups and varying degrees of 
disease susceptibility is often limited by a number of factors. RSV infections in healthy 
individuals are usually self-limited and do not require hospitalization [51]. Thus, only the 
most severe manifestations of RSV disease can be studied in detail as the milder forms 
often go unreported [51]. Additionally, most studies are based on samples obtained from 
non-invasive procedures (i.e. PBMCs, nasal washes, lung aspirates, etc.) as there is 
limited accessibility to the LRT of infected individuals [51]. Needless to say, the 
numerous ethical concerns surrounding RSV studies in the LRT of healthy volunteers 
pose an even greater challenge in the study of the RSV disease spectrum [1]. One way to 
overcome such hindrances is to use appropriate animal models. These models provide a 
more dynamic and flexible setting to test hypotheses in vivo, addressing some of those 
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inquiries regarding the mechanism of disease pathogenesis. Ultimately, animal models 
are necessary tools to assess the safety and efficacy of novel vaccines and therapeutics 
during preclinical trials [67].   
Currently, human RSV disease can be studied in the laboratory by the use of two 
major types of animal modeling. Heterologous host-virus models involve the infection of 
semi-permissive animals like chimpanzees, sheep, cotton rats and mice with human RSV 
[6, 67]. On the other hand, cognate host-virus models are based on other pneumoviruses 
infecting their natural hosts. Examples of the latter include bovine RSV (BRSV) and 
pneumonia virus of mice (PVM) [6, 67]. While there are unique advantages and 
disadvantages to each individual animal model, it is important to realize that not a single 
experimental system in isolation can be used to answer all the questions regarding the 
human RSV disease spectrum. Besides, the main hypothesis and specific objectives of 
one’s research should dictate what the most appropriate disease model is for use in the 
laboratory.  
 
1.4.1 Heterologous host-virus models. 
 
1.4.1.1 Chimpanzee 
 
It has been documented that young chimpanzees (i.e. 15-18 month old) are highly 
permissible to the virus, usually leading to productive infections [68]. Most animals 
exhibit URT disease symptoms like rhinorrhea, sneezing and coughing after primary 
RSV infection [67, 69, 70]. Unfortunately, a number of researchers have reported that 
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chimpanzees experimentally infected with RSV do not show signs or symptoms of LRT 
disease [67, 70]. The high genetic and anatomical similarities between chimpanzees and 
humans are major advantages of this model [67, 69]. However, high cost, limited 
accessibility, and the numerous ethical constrains of working with such animals restricts 
the use of this model for RSV pathogenesis studies [67, 68, 70]. Currently, the 
chimpanzee model is primarily used for the evaluation of novel vaccine candidates [67, 
68].   
 
1.4.1.2 Sheep 
 
Recently, the use of a newborn lamb model has been proposed to be more suitable 
for RSV pathogenesis studies in vivo [51, 67]. Disease outcomes of experimentally 
infected neonatal lambs resemble closely the pathology observed in infants with RSV 
bronchiolitis [51]. Unlike the chimpanzee model, there is evidence of both upper and 
lower respiratory tract disease in newborn (2-3 days old) lambs infected with RSV [51, 
67]. These animals presented with fever, coughing, bronchiolitis resulting from 
entrapment of cellular debris, mild interstitial pneumonia, and a prominent infiltration of 
neutrophils, macrophages and effector lymphocytes in the lungs [67]. In addition, high 
concentrations of IL-8 and TNF-α were detected in the lungs of these lambs and virus 
replication in the airways was robust [67]. Importantly, the respiratory tract of sheep and 
humans share a similar anatomical structure [51]. Unlike rodents, alveolar development 
in both species starts preterm [51]. Despite the fact that the availability of reagents and 
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molecular tools to analyze sheep samples has greatly increased over the years, it still 
remains a big disadvantage of this animal model for RSV research purposes [67].  
 
1.4.1.3 Cotton rat 
 
Over the past few decades, the cotton rat Sigmodon hispidus has become widely 
utilized for the study of RSV pathogenesis [1, 67]. In addition to being susceptible to 
RSV, these animals can support the replication of other human respiratory pathogens like 
influenza virus, PIV, and metapneumovirus [1]. Unlike most rodents, cotton rats are 
highly permissive to RSV and infections can be established throughout life [1, 69]. Thus, 
this model has been used to further study the differences in RSV disease susceptibility 
that occur in infants, elderly, and immunosuppressed populations [1]. In 1971, Dreĭzin et 
al. were the first group to describe the experimental infection of RSV in cotton rats [71]. 
Since then, it has been demonstrated that these animals are approximately 100-fold more 
permissive to RSV than inbred laboratory mice [1, 67, 69].  While RSV-infected cotton 
rats do not show major clinical symptoms like nasal discharge and changes in weight, in 
terms of histopathological lesions, these animals display mild signs of bronchiolitis and 
pneumonia following RSV infection [1, 67]. There is evidence that both the upper and 
lower respiratory tract can become infected with RSV [67]. However, virus replication 
lasts longer in the nose than in the lungs [1]. Following RSV infection, the inflammatory 
response is characterized by lymphocyte infiltration into the airways and increased levels 
of CCL3, CCL2 and IFN-γ in the site of infection [67]. Importantly, cotton rats have 
served as a surrogate model used to recapitulate the FI-RSV-enhanced disease previously 
	   20 
reported in human subjects. Thus, this model has become an indispensable tool to assess 
the safety of vaccines, antivirals and immunotherapeutics in preclinical studies [1, 67, 
69]. Nevertheless, there are several drawbacks that might limit the use of such animal 
model system. For instance, RSV-infected cotton rats do not present with overt signs of 
disease [1]. Additionally, these small animals are difficult to handle, reagent availability 
is limited, and transgenic or knockout strains have yet to be developed [1, 67].  
 
1.4.1.4 Mice 
 
Initially described in 1979 by Prince et al., the inbred laboratory mouse model 
has become quite popular over the years as a means to study experimental human RSV 
disease in vivo [6, 67, 72]. Most wild-type inbred mice are considered semi-permissive 
hosts for RSV [67]. Virus replication is limited, and even in the most susceptible strains, 
such as Balb/c, a high virus inoculum is required to obtain a productive infection [67, 70]. 
Clinical signs are moderate and are usually restricted to changes in total body weight, 
reduced mobility and rough coats [67]. As a result, different RSV strains (e.g. A/long) 
and human clinical isolates (Line 19, RSV 2-20) can be used to mimic a more severe 
disease presentation in mice [67]. Overall, the bronchoalveolar lavage fluid (BALF) of 
Balb/c mice infected with a high dose of RSV show elevated levels of TNF-α, IL-6, IFN-
γ, CCL3, CCL5, and CXCL1 [67]. Effector lymphocytes are the most prominent cell type 
infiltrating the lungs following infection in this animal model [67]. Histopathological 
lesions include perivasculitis and peribronchiolitis, and in some cases, interstitial 
pneumonia is observed [67, 68]. In terms of age, experimentally infected neonatal Balb/c 
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mice develop asthma-like symptoms such as airway hyperreactivity, mucus 
overproduction, eosinophilia and a distinct Th2-biased response [51, 67, 73]. In contrast, 
RSV infection in adult Balb/c mice induces a Th1-biased response, with high 
concentrations of IFN-γ in both lung and BALF [68, 73]. A clear downside of using this 
animal model is the numerous differences between innate and adaptive immune 
responses of humans and mice [67]. Additionally, pneumoviruses are known to be 
species-specific, thus studies in cognate hosts are better suited to obtain an understanding 
of fundamental immune-mediated mechanisms of severe infection [13].  Other limitations 
in using rodents as animal models include the distinct neutrophil and lymphocyte ratios in 
blood, and differences in lung anatomy [13, 67, 69]. Nonetheless, the RSV mouse model 
has major advantages, such as the vast availability of reagents, immunological tools, 
knockout and transgenic strains, cost-effectiveness and ease of housing and handling [6, 
67, 70]. 
 
1.4.2 Cognate host-virus models. 
 
1.4.2.1 Mice and Pneumonia Virus of Mice (PVM) 
 
Better animal models to study RSV pathogenesis can arise from the use of other 
pneumoviruses matched to their cognate hosts. In turn, this may provide us with a more 
accurate representation of natural infection and disease [1]. In the last thirty years, the 
pneumonia virus of mice (PVM) has been considered as a mouse model of natural RSV 
disease [13, 51]. PVM is closely related to RSV, both belonging to the same viral family 
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and subfamily, and inducing similar disorders in their natural hosts [74]. Unlike RSV 
infection in mice, PVM replicates in the lower airways to extremely high titers in 
response to as little as 10 plaque-forming units (pfu) of virus inoculum [12, 13, 51, 69]. 
In addition, PVM infections can lead to high mortality rates in susceptible mouse strains 
(e.g. 100% in Balb/c) [67]. However, a lower PVM inoculum dose or a more resistant 
mouse strain can change disease severity [67]. There are two fully characterized strains of 
PVM, PVMJ3666 and PVM-15. The genome sequence and organization of these strains 
is 99.7% identical to one another [13]. As both RSV and PVM are part of the same viral 
genus, they have very similar genomic structures and all PVM proteins have respective 
functional counterparts with RSV [13].  The virus has a preference for the bronchiolar 
epithelium, which mainly induces LRT disease symptoms such as tachypnea, airway 
obstruction and difficulty breathing [67]. Thus, it becomes very difficult to obtain URT 
disease presentation using the PVM infection model.  
PVM-infected mice present with elevated levels of CCL2, CCL3, CCL5, CXCL1, 
TNF-α, IL-6, and IFN-γ in the lower airways. Neutrophils are the main cell population 
recruited into the LRT during active infection, playing a critical role in both PVM and 
RSV pathogenesis [13, 67, 68, 75]. As a result, histopathological lesions following PVM 
infection often result in peribronchiolitis with progression to edema, alveolitis, and 
hemorrhage [67]. Similar to RSV in humans, age is considered a major determinant in 
PVM-mediated clinical disease [67, 76]. Unfortunately, there are disadvantages of using 
PVM as a model system to study RSV pathogenesis. For instance, there is no direct 
cross-reactivity between these two viruses as both pathogens are inherently different (e.g. 
PVM F protein shares only 40% animo acid sequence identity to that of RSV) [1, 67, 68]. 
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Thus, the study of antigen-specific acquired immunity is very limited [75, 77]. 
Nevertheless, there are sufficient similarities in the molecular pathogenesis that make 
PVM suitable for the study of RSV-induced inflammation and severe respiratory disease. 
Apart from the numerous advantages of using mice in the laboratory, PVM also serves as 
an appropriate platform for the development of novel approaches to combat severe RSV 
disease [67, 75].  
 
1.4.2.2 Cattle and Bovine RSV (BRSV) 
 
A natural pathogen of cattle, BRSV is considered a major cause of respiratory 
disease in calves [1, 67, 68, 74]. The virus was discovered and further described by 
Paccaud and Jacquier in 1970 [78].  Since then, it was found that RSV and BRSV are 
antigenically very similar, with 80% homology between the two viruses [1, 6, 74, 79]. In 
addition, BRSV-mediated disease in cattle closely resembles that of RSV in humans [6, 
67, 80]. For instance, young age is a major factor dictating disease severity in both 
infection models [1, 67, 81]. BRSV clinical outcomes can range from subclinical to fatal, 
with worsening of symptoms occurring in calves less than 6 months old [1, 68]. 
Aerosolized infection of calves with BRSV starts with non-specific symptoms like fever 
and anorexia, which is then followed by both upper and lower respiratory tract clinical 
signs like rhinitis, cough, rapid breathing, wheezing, dyspnea, and hypoxemia [1, 67, 68, 
74]. Similar to both RSV and PVM, strong neutrophilic infiltration occurs in the lower 
airways, and recruitment of effector lymphocytes is usually limited [1, 67, 68, 80]. BRSV 
histopathology in calves is characterized by bronchiolitis, interstitial pneumonia, mucus 
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overproduction, atelectasis, and in most severe cases, bullous emphysema [1, 67, 68, 81]. 
High concentrations of TNF-α and IL-6 were detected in the BALF of calves with LRT 
disease [1, 67, 68, 74]. In contrast to RSV disease in humans, bacterial co-infections with 
Mannheimia, Haemophilus and Pasteurella species may occur in cattle infected with 
BRSV, bovine PIV-3, bovine herpesvirus 1 (BHV-1), and/or bovine viral diarrhea virus 
(BVDV) [82]. This subsequently leads to what is commonly known as bovine respiratory 
disease complex (BRDC) [67, 74, 81, 82].  
Despite sharing similar genetics, epidemiology and clinical disease features with 
RSV, the BRSV infection model has several disadvantages. Though the availability of 
bovine molecular tools and immunological reagents has rapidly increased over the past 
few decades, it still remains relatively poor compared to that of rodents. In addition, the 
high cost of calves also limits the use of this model to study RSV pathogenesis [51, 74]. 
Special veterinary expertise in housing and handling of these animals is required, and 
more importantly, BRSV and RSV are inherently different pathogens after all [67]. 
Regardless, the BRSV infection system in a large animal model has all the necessary 
qualities to successfully assess the efficacy of novel RSV vaccines and therapeutics in 
preclinical trials [68].   
 
1.5 Immunomodulators 
 
1.5.1 Definition 
 
The appropriate stimulation of the immune system can improve the immediate 
control of pathogens, especially in situations where this fails at protecting the host from 
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infection. Immunomodulators are substances known to modify and correct the nature of 
host’s immune responses [83-85]. These agents can be obtained from endogenous or 
exogenous sources. Examples include cytokines, chemokines, growth factors, 
immunoglobulins, compounds of synthetic or natural origin, and microbial products [83, 
86-88]. Immunomodulators can exert their function in either an antigen-specific or an 
antigen-independent manner [86, 88]. In addition, they can be further subdivided into 
immunoadjuvants, immunostimulators, and immunosuppresants [85, 88]. 
Immunomodulators are currently being used as vaccine adjuvants, as well as in strategies 
to combat various types of cancers, microbial infections, and autoimmune conditions [83-
85, 87, 89]. 
 
1.5.2 Applications 
 
Most immunomodulators act at the level of the innate immune system [90]. The 
engagement of PRRs and their respective signal transduction pathways leads to the 
induction of the inflammatory response. Vaccine adjuvants are immunomodulators 
known to enhance the immunogenicity of a particular antigen [91]. These compounds can 
either be part of the immunogen itself, or be separately added to the formulation [92]. For 
instance, whole microbial preparations, either attenuated or killed, are thought to have 
both adjuvant and immunomodulatory properties [88]. The attenuated Mycobacterium 
strain used in the Bacillus Calmette–Guerin (BCG) vaccine is a perfect example of this. It 
is primarily used for immunization against tuberculosis and leprosy [92]. Additionally, 
this microbial immunomodulator has also been used in cancer immunotherapies [88, 91]. 
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BCG strain works as an adjuvant because it contains several TLR ligands like 
peptidoglycans, lipopolysaccharides (LPS), cytosine-phosphate-guanosine 
oligodeoxynucleotides (CpG ODNs), and flagellin [92]. Furthermore, BCG promotes 
cell-mediated immune responses against tumor-associated antigens, thus currently being 
a routine treatment for patients with superficial bladder cancer [91, 93].  
Imiquimod, a synthetic imidazoquinoline amine and commercially known as 
Aldara®, is another example of an immunomodulator used in cancer immunotherapy [94]. 
Approved by the FDA in 2004, imiquimod is used as a topical ointment for the treatment 
of primary superficial basal cell carcinoma (BCC) [95].  This compound binds to the 
endosomal TLR7 of plasmacytoid DCs (pDCs), leading to the production of pro-
inflammatory cytokines like IFN-α, TNF- α, IL-12, among others [94, 95]. As a result, 
skin macrophages and other innate immune cells become activated, releasing reactive 
oxygen species (ROS) and toxic byproducts [95]. It is thought that high concentrations of 
imiquimod can lead to the specific apoptosis of tumor cells in the skin [94, 95].  
Moreover, the family of imidazoquinolines tends to promote both anti-viral and Th1-
biased immune responses in vivo [94]. Hence, imiquimod, is also used to treat human 
papillomavirus (HPV)-induced genital warts [96]. 
Immunomodulators can also be used to combat microbial infections [84, 86]. The 
rationale behind this approach originates from the fact that these compounds mediate the 
activation of immune cells involved in pathogen control and clearance (i.e. macrophages, 
NK cells, etc) [87]. In addition, immunomodulators can play a role in the regulation of 
pathogen-induced immunopathology. For instance, a Th1-biased immune response is 
required for the protection against fungal infections [86, 97]. Immunocompromised 
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patients lack the ability to mount appropriate immune responses against most pathogens. 
In the case of human immunodecifiency virus and acquired immune deficiency syndrome 
(HIV/AIDS) patients, a high proportion of them present with low neutrophil cell counts 
and other cytopenias in the blood [87, 98]. Thus, these individuals are at a higher risk of 
acquiring bacterial and fungal infections [87]. According to several clinical studies, 
colony-stimulating factors (CSFs) are able to revert the state of neutropenia in these 
individuals [86]. There is evidence that granulocyte-macrophage CSF (GM-CSF) added 
as an adjunct to amphotericin B therapy decreases mortality rates in neutropenic patients 
with invasive fungal infections [86, 99]. In addition, macrophage CSF (M-CSF) has been 
shown to increase antifungal activity of murine macrophages, monocytes and neutrophils 
[84]. This is important because these effector cells can further complement and synergize 
with the intrinsic antifungal activity of azole fungistatic drugs [84].  
Autoimmunity arises when the mechanisms involved in self-nonself 
discrimination fail at making such distinction [96]. As a result, exacerbated immune 
responses are mounted against self-antigens, often leading to severe immunopathologies 
[100]. Immunomodulators that suppress or neutralize these overzealous responses can 
ameliorate the symptoms of systemic autoimmune diseases. For instance, the persistent 
activation of pDCs during systemic lupus erythematosus (SLE) leads to the constant 
induction of IFN-α [96, 100]. Hence, patients with active SLE tend to have elevated 
levels of this IFN in the blood [96]. In addition, human pDCs are known to express 
endosomal TLR7 and TLR9 [100]. It is thought that either self-DNA or immune 
complexes composed of autoantibodies with RNA binding nucleoproteins can be 
engulfed by pDCs and serve as ligands for those receptors [96]. Thus, a number of 
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synthetic ODN antagonists have been generated to specifically inhibit TLR7 and TLR9 
signaling transduction pathways [101]. One research group demonstrated that the 
immunoregulatory sequence (IRS) 954 inhibits both TLR7 and TLR9 signaling in mice 
[101]. In the context of experimental SLE, animals that received IRS 954 treatment 
during the onset of SLE had lower autoantibodies in the serum, as well as less symptoms 
and increased survival than untreated mice [101]. IRS 954 is currently being evaluated in 
preclinical trials as a potential treatment for SLE in humans [96]. 
 
1.5.3 Benefits 
 
Immunomodulators have become an attractive alternative to conventional 
interventions in many clinical settings. These compounds can provide an optimal innate 
stimulation of the host’s immune system, resulting in a broadened capacity to combat 
numerous insults. Their benefit stems from their ability to naturally shape innate immune 
responses via the activation of key PRR signaling pathways. In the context of viral 
infections, these agents are able to enhance anti-viral immunity by promoting the 
recruitment of macrophages, DCs, and NK cells, and augmenting the production of IFN 
proteins [83, 84]. Immunomodulators often cause fewer adverse effects than existing 
drugs (i.e. antivirals, antibiotics, etc.), are less likely to mediate antimicrobial resistance, 
and work synergistically with chemotherapeutic compounds. When used as adjuncts in 
combinational therapies, these can shorten the course of treatment and overall drug 
dosage. [83-85].  
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1.6 P-I-P 
 
P-I-P is a novel immunomodulator consisting of polyinosinic-polycytidylic acid 
(poly I:C), innate defense regulator (IDR) peptide 1002, and 
poly[di(sodiumcarboxylatoethylphenoxy)]phosphazene (PCEP). Previously, our group 
demonstrated that when using this immunomodulator as a vaccine adjuvant in 
combination with a truncated version of the RSV fusion (F) protein, this formulation is 
able to induce long-lasting mucosal and systemic immune responses against RSV in 
several animal model systems [102-104]. Based on these data, it is speculated that this 
immunomodulator has the potential to be employed in applications other than vaccines, 
as an alternative strategy to prevent or treat infectious diseases.  
 
1.6.1 Poly I:C 
 
Poly I:C is a synthetic analogue of double stranded RNA (dsRNA), considered to 
be a molecular pattern associated with viral infections [102, 105, 106]. This compound is 
able to activate the innate immune system via PRR signaling pathways [107]. Notably, 
poly I:C is mainly recognized by endosomal TLR3 and cytoplasmic RLRs, such as RIG-I 
and MDA-5 [102, 105-107]. In mammals, TLR3 expression has been detected in multiple 
cell types like ECs, fibroblasts, tumor cells, keratinocytes, DCs, macrophages and B cells 
[105, 107]. In contrast, RIG-I and MDA-5 expression is more ubiquitous as almost every 
tissue expresses it the cytosol [107]. The engagement of poly I:C with these receptors 
mediates the recruitment and activation of several transcription factors, specifically NF-
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κB, IRF3 and IRF7 [105]. Consequently, these signaling events lead to the production of 
pro-inflammatory cytokines and type I IFNs [102, 105, 107]. In addition, poly I:C can 
increase the expression of co-stimulatory molecules in antigen-presenting cells (APCs), 
and promote Th1 immune responses in vivo [107-109]. Overall, the intrinsic 
immunostimulatory properties of poly I:C make it an attractive compound to be use in 
applications ranging from vaccine adjuvants to cancer immunotherapies.  
 
1.6.2 IDR peptide 1002 
 
IDR peptide 1002 is a synthetic cationic peptide derived from bovine bactenecin, 
a 12-amino-acid cathelicidin produced by bovine neutrophils [110-112]. Many research 
groups have described the mechanism of action of such peptides. Both naturally produced 
and synthetic IDR peptides can interact with G protein-coupled receptors (GPCRs) on the 
surface of many cells or directly enter into the cytosol through lipid rafts [113]. Once 
inside the cell, these peptides bind several intracellular receptors like glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and sequestosome-1 (SQSTM1), leading to the 
activation of multiple signaling pathways involved in the initiation of innate immune 
responses [113]. Hence, IDR peptides are known to possess a vast array of 
immunomodulatory activities both in vitro and in vivo, including induction of cytokine 
and chemokine production, regulation of host’s cellular gene expression, immune 
activation and apoptosis, modulation and control of the levels of pro-inflammatory 
cytokines, ROS and toxic byproducts released by immune cells during infection, 
stimulation of chemotaxis and leukocyte recruitment into the site of infection, promotion 
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of angiogenesis and wound healing [110, 113, 114]. There is evidence suggesting that 
IDR peptide 1002 is a better inducer of chemokines in vitro than IDR-1, another well-
known bactenecin-derived peptide [110, 111, 113]. In addition, IDR peptide 1002 
protected mice against invasive Staphylococcus aureus and Escherichia coli infections by 
enhancing monocyte and neutrophil recruitment into the site of infection [110, 111, 113]. 
It is thought that this peptide possesses anti-inflammatory properties, as it is able to 
suppress pro-inflammatory immune responses in vivo [113]. Altogether, the unique 
biological properties of IDR peptide 1002 confirm its intrinsic immunomodulatory 
capacity and elucidate its potential at combating human infectious diseases.   
 
1.6.3 PCEP 
 
Polyphosphazenes are high-molecular weight synthetic polymers consisting of an 
alternating phosphorus-nitrogen backbone with organic side groups attached to each 
phosphorous atom [115]. The properties of these macromolecules can be easily modified 
by the incorporation of different ionic moieties to their structural backbone [115, 116]. 
PCEP is a water-soluble, new generation polyphosphazene polyelectrolyte known to have 
strong adjuvant activity in vivo [116]. According to a number of animal studies, PCEP 
induces long-lasting immune responses to a variety of bacterial and viral protein antigens 
[117]. In the context of vaccines, this polyphosphazene has the potential to form non-
covalent protein-polymer complexes in solution, promote balanced cell-mediated and 
humoral immune responses, act as a delivery system, and strongly modulate the early 
innate immune response at the site of immunization [115, 117-119]. In addition, it has 
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been shown that intranasal delivery of PCEP with influenza virus X:31 antigen can 
induce both systemic and mucosal immune responses in mice [117]. One research group 
revealed that the intramuscular delivery of PCEP in mice activated the NLRP3 
inflammasome, along with the production of IL-1β and IL-18 within the tissue [120]. 
However, the complete mechanism of action of polyphosphazenes in vivo remains to be 
fully elucidated. Nonetheless, these macromolecules are currently being used in several 
biomedical settings including novel drug delivery systems, adjuvants in vaccine 
formulations, hydrogel-forming materials for tissue protheses, among others [116]. 
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2. HYPOTHESIS AND OBJECTIVES 
 
Hypothesis: 
As mentioned previously, P-I-P has been shown to be a successful adjuvant platform 
in the context of an RSV vaccine using F protein as protective antigen. Taking into 
consideration the immunomodulatory properties of this adjuvant platform, we anticipate 
that the sole stimulation of the innate immune system by the use of this formulation will 
protect susceptible Balb/c mice against a lethal dose of PVM. Additionally, we predict 
that the protection induced by P-I-P against PVM disease should pose minimal side 
effects to the animals. 
 
Objectives: 
The first objective is to assess the potential of P-I-P to protect adult Balb/c mice 
against lethal PVM-15 infection based on clinical disease, survival scores, virus 
replication and lung histopathology. In addition, we will conduct gene and protein 
expression studies to quantify key factors involved in host defense in response to P-I-P 
treatment in the absence of virus challenge.  
The second objective is to examine the nature of the inflammatory response 
induced by P-I-P treatment in order to delineate a possible mechanism of action in vivo. 
We will conduct studies to measure the mRNA and protein expression of cytokines, 
chemokines, and IFNs in the lungs, as well as the infiltration of neutrophils, alveolar 
macrophages, DCs, NK cells and eosinophils within the tissue.  
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Lastly, the third objective is to determine the optimal time of P-I-P treatment to 
use for prophylaxis. We will monitor clinical scores for weight loss, disease signs and 
survival. 
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3. MATERIALS AND METHODS 
 
3.1. Cell line and virus propagation.  
 
PVM-15 was propagated in Baby Hamster Kidney 21 (BHK-21, ATCC, 
Manassas, VA, USA) cells in Dulbecco’s Modified Eagle Medium (DMEM, Sigma-
Aldrich, St. Louis, MO, USA) containing 2% fetal bovine serum (FBS, Gibco, Thermo 
Fisher Scientific, Waltham, MA, USA), 0.1 mM non-essential amino acids (Thermo 
Fisher Scientific, Waltham, MA, USA), 10 mM HEPES (Thermo Fisher Scientific, 
Waltham, MA, USA), and 50 µg/ml gentamicin (Thermo Fisher Scientific, Waltham, 
MA, USA) [13]. These cells were grown to a confluency of ~75-80% in T150 flasks (BD 
Biosciences, Franklin Lakes, NJ, USA). Then, the medium was removed from the flask 
and the cell monolayers were gently washed with DMEM. Afterwards, the cells were 
infected with PVM15 at a multiplicity of infection (MOI) of 0.1 in an initial volume of 5 
ml. The infected flasks were immediately placed on top of a rocking platform inside a 
37°C room for 1.5 hr. Next, 11 ml of medium were added to each flask and afterwards 
the cells were incubated at 37°C, 5% CO2 for 3 days. The virus was harvested by 
scraping the cell monolayers into the supernatant using a 39 cm Handle/3.0 cm blade cell 
scraper (Corning Inc., Corning, NY, USA), and pipetting up and down multiple times to 
further disrupt cellular debris. This mixture was used as viral stock to infect additional 
flasks of BHK-21 cells or aliquoted, frozen immediately in liquid nitrogen, and stored in 
an -80°C freezer for long-term use. 
 
	   36 
3.2. Treatment formulations and challenge of mice with PVM-15. 
 
To determine the effects of P-I-P on the innate responses over time, five to six 
week-old female Balb/c mice (Charles River Laboratories, Saint-Constant, QC, Canada) 
were given 20 µl of PBS or P-I-P intranasally, and lungs were collected at selected time 
points for further analysis. To evaluate the ability of P-I-P to elicit protection from viral 
infection, five to six week-old female Balb/c mice were given intranasal treatments of 
PBS or P-I-P, and challenged 1, 3, 4, 5, or 6 days later with PVM. The P-I-P formulation 
contained phosphate-buffered saline (PBS, Gibco, Thermo Fisher Scientific, Waltham, 
MA, USA), 20 µg low-molecular weight poly I:C (Invivogen, San Diego, CA, USA), 40 
µg IDR peptide 1002 (Genscript, Piscataway, NJ, USA), and 20 µg PCEP (Idaho 
National Laboratory, Idaho Falls, ID, USA). The 1:2:1 ratio of the P-I-P formulation was 
previously determined to be optimal when used as an adjuvant [121]. A full description 
of treatment groups in the experiments is provided in Table 3.1. 
On the day of challenge, mice were inoculated intranasally with 3000 pfu of PVM-15 
in 50 µl. Animals were placed under light anesthesia with isoflurane during this 
procedure. Five mice per group were chosen exclusively to be scored and weighed daily 
according to a pre-established guideline used by our Animal Care unit. A score of 0 is 
given to mice with weight loss of 0 to 3.9%. A score of 1, 2 and 3 represents a weight 
loss of 4 to 10.9%, 11 to 19.9%, and greater than 20% respectively. If the latter situation 
was observed, the animal would be euthanized even if the trial had not yet ended. The 
remaining mice were used for lung sample collection at various time points throughout 
the experiment. On the last day of the trial, day 14 post-infection (p.i.), all remaining 
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mice were euthanized with isoflurane. In some experiments, the lungs of surviving mice 
were collected on day 14 p.i. for further analysis. All animal trials were conducted 
according to the guidelines established by the University Committee on Animal Care and 
Supply (UCAS) at the University of Saskatchewan in accordance with the Canadian 
Council on Animal Care (CCAC). 
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Table 3.1: Detailed description of each treatment group in animal trials. 
 
 Treatment 
Groups Formulation Purpose 
A PBS  20 µl PBS as treatment. No challenge. Gene and protein expression studies in response to P-I-P alone. 
B P-I-P 
20 µg LMW poly I:C + 40 µg IDR 
peptide + 20 µg PCEP in 20 µl as 
treatment. No challenge. 
Gene and protein expression 
studies in response to P-I-P alone. 
C PBS/Medium 20 µl PBS as treatment. 50 µl medium as challenge. Protection studies. 
D P-I-P/PVM 
20 µg LMW poly I:C + 40 µg IDR 
peptide + 20 µg PCEP in 20 µl as 
treatment. 50 µl 3000 pfu PVM as 
challenge. 
Protection studies. 
E PBS/PVM 20 µl PBS as treatment. 50 µl 3000 pfu PVM as challenge. Protection studies. 
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3.3. Collection and processing of lung samples. 
 
At 6, 24, 96 and 144 hr post-treatment (p.t.) or on days 0, 3 and 5 p.i., five mice per 
group per time point were euthanized with an overdose of isoflurane. Lung samples were 
collected to evaluate virus titers and expression of innate immune response genes and 
proteins. The single-lobed left lung was clamped off and removed into a 2 ml screwcap 
tube containing ~1 ml of 2.4 mm zirconia beads (BioSpec Products Inc, Bartlesville, OK, 
USA) and 1 ml of TRIzol® reagent (Thermo Fisher Scientific, Waltham, MA, USA). This 
lung was used for mRNA extraction and gene expression studies. The multi-lobed right 
lung was removed into a tube containing 1 ml of 2.4 mm zirconia beads, and 1 ml of 
DMEM supplemented with 0.1 mM non-essential amino acids, 10 mM HEPES, 50 µg/ml 
gentamicin, and 1X antibiotic/antimycotic (Thermo Fisher Scientific, Waltham, MA, 
USA). These lungs were used for virus titrations, as well as cytokine, chemokine and IFN 
multiplex ELISAs. Both lungs were homogenized for 10 sec at 4,800 rpm using a mini 
bead-beater (BioSpec Products Inc., Bartlesville, OK, USA), and centrifuged at 4°C for 1 
min at 10,000 x g to remove gross debris. Immediately, all samples were aliquoted, flash-
frozen in liquid nitrogen and stored at -80°C. 
 
 
3.4. Viral titrations and qPCR assays for PVM quantification. 
 
BHK-21 cells were plated on 96-well plates at a confluency of 80%. In separate 96-
well dilution plates, 100 µl of the collected lung homogenates were added to the first row 
of the plates, and seven 10-fold serial dilutions were made in the remaining wells. Then, 
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100 µl of these dilutions were transferred in duplicates onto the BHK-21 cell monolayers. 
After 72 hr of incubation at 37°C and 5% CO2, the cells were fixed with an ice-cold 
mixture of 3 parts acetone to 1 part methanol. The plates were washed three times with 
PBS before the blocking step and in between each antibody incubation period. The plates 
were blocked with 5% goat serum (Thermo Fisher Scientific, Waltham, MA, USA) 
solution for 30 min, followed by 2.5 hr incubation with a 1:500 dilution of rabbit 
polyclonal anti-PVM nucleoprotein antibody in 1% goat serum. Finally, a 1:500 dilution 
of a secondary Alexafluor® 488 goat anti-rabbit antibody (Thermo Fisher Scientific, 
Waltham, MA, USA) was added to the wells for 1 hr. Viral plaques were visualized and 
counted using a fluorescent microscope (Carl Zeiss Canada Ltd., Toronto, ON, Canada).  
Absolute PVM copy numbers were calculated via quantitative real-time PCR (qPCR) 
using a 1:5 serial dilution standard curve of stock PVM RNA in nanograms. The primers 
used were specific to the small hydrophobic (SH) gene of the virus. Unknown RNA 
concentrations were calculated following the equation of the curve, and copy numbers 
were determined according to Avogadro’s number and the SH gene amplicon size. 
 
3.5. Gene expression analysis of chemokines, cytokines and interferons by qPCR. 
 
Total RNA was extracted from the single-lobed left lung in TRIzol® reagent 
according to manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, USA). 
Complementary DNA (cDNA) synthesis was performed using the QuantiTect Reverse 
Transcription kit (Qiagen, Venlo, Limburg, Netherlands). qPCR was carried out using 
FastStart SYBR Green Master (Roche, Basel, Switzerland). The primers (Thermo Fisher 
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Scientific, Waltham, MA, USA) and annealing temperatures used in the experiments are 
listed in Table 3.2. The qPCR reactions were performed according to the following 
parameters: 1st step at 95°C for 10 min, 2nd step repeated 40X initially at 95°C for 15 sec, 
then annealing temperature for 30 sec, and lastly 72°C for 30 sec. Finally, the 3rd step was 
repeated 31X starting at 65°C with 1.0°C increments ending at 95°C. This last step was 
mainly to acquire data for the melt curve analysis. All results were normalized based on 
the average of the β-actin levels of all PBS or PBS/Medium control animals.   
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Table 3.2: List of primers used in qPCR experiments. 
 
 
Target 
gene 
Direction Sequence 
Amplicon 
size 
Annealing 
Temp (°C) 
β-actin 
Forward 5’ ACTGGGACGACATGGAG 3’ 
266bp 57.5 
Reverse 5’ GTAGATGGGCACAGTGTGGG 3’  
SH 
Forward 5’ ACCAGCAGCCGTATTGGCACA 3’  
102bp 57.5 
Reverse 5’ GCTGCAGGCCATTATCAGCGCA 3’  
IFN-γ 
Forward 5’ TCAAGTGGCATAGATGTGGAAGAA 3’ 
92bp 57.5 
Reverse 5’ TGGCTCTGCAGGATTTTCATG 3’ 
IFN-α 
Forward 5’ CCTGTGTGATGCAACAGGTC 3’ 
209bp 59.3 
Reverse 5’ TCACTCCTCCTTGCTCAATC 3’ 
IFN-β 
Forward 5’ ATCATGAACAACAGGTGGATCCTCC 3’ 
419bp 63.9 
Reverse 5’ TTCAAGTGGAGAGCAGTTGAG 3’ 
CXCL10 
(IP-10) 
Forward 5’ ATGACGGGCCAGTGAGAATG 3’ 
249bp 67.6 
Reverse 5’ GAGGCTCTCTGCTGTCCATC 3’ 
CCL3   
(MIP-1α) 
Forward 5’ CTTCTCTGTACCATGACACTC 3’ 
208bp 57.5 
Reverse 5’ AGGTCTCTTTGGAGTCAGCG 3’ 
CCL2  
(MCP-1) 
Forward 5’ CTTCTGGGCCTGCTGTTCA 3’ 
127bp 57.5 
Reverse 5’ CCAGCCTACTCATTGGGATCA 3’ 
CXCL2 
(MIP-2) 
Forward 5’ TGCGCCCAGACAGAAGTCATAGC 3’ 
129bp 63.9 
Reverse 5’ GCTCTAGAGTCAGTTAGCCTTGCCTTTG 3’ 
CXCL1 
(KC) 
Forward 5’ ATGAGCTGCGCTGTCAGTGC 3’ 
247bp 56.3 
Reverse 5’ CACCAGACGGTGCCATCAGA 3’ 
IL-12β 
(p40) 
Forward 5’ GACCCTGCCCATTGAACTGGC 3’ 
415bp 57.5 
Reverse 5’ CAACGTTGCATCCTAGGATCG 3’ 
TNF-α 
Forward 5’ AGGCACTCCCCCAAAAGATG 3’ 
203bp 57.5 
Reverse 5’ CTGCCACAAGCAGGAATGAG 3’ 
IL-1β 
Forward 5’ GTGTGGATCCCAAGCAATAC 3’ 
173bp 55.0 
Reverse 5’ GTCCTGACCACTGTTGTTTC 3’ 
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IL-6 
Forward 5’ GTGGCTAAGGACCAAGACCA 3’ 
95bp 59.2 
Reverse 5’ TAACGCACTAGGTTTGCCGA 3’ 
IL-10 
Forward 5’ GCTGCCTGCTCTTACTGACT 3’ 
81bp 57.5 
Reverse 5’ CTGGGAAGTGGGTGCAGTTA 3’ 
TGF-β 
Forward 5’ AGGGCTACCATGCCAACTTC 3’ 
168bp 57.5 
Reverse 5’ CCACGTAGTAGACGATGGGC 3’ 
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3.6. Multiplex ELISAs for quantification of chemokine, cytokine and interferon 
proteins in the lung. 
 
The multi-lobed right lungs of 5 mice per group per time point were individually 
collected, homogenized in DMEM, aliquoted with 1X SIGMAFASTTM Protease Inhibitor 
solution (Sigma-Aldrich, St. Louis, MO, USA) and flash-frozen on days 0, 3 and 5 p.i. 
The MSD Multi-Spot V-PLEX assay for the pro-inflammatory panel 1 (TNF-α, IL-1β, 
IL-6, IL-12, IL-10 and CXCL1) and the MSD Multi-Array Mouse Cytokine Ultra-
sensitive Assay for CCL2 were used to quantify cytokine, type II IFN, and chemokine 
levels in the lungs according to manufacturer’s instructions (Meso Scale Discovery, 
Rockville, MD, USA). 
 
3.7. Cell influx analysis by flow cytometry. 
 
Both multi- and single-lobed lungs were perfused with 5 ml of Hanks balanced salt 
solution (HBSS, Thermo Fisher Scientific, Waltham, MA, USA) containing 5% FBS. 
Then, the tissues were mechanically disrupted using a gentle MACS dissociator 
according to the manufacturer’s instructions (Miltenyi Biotec Inc., San Diego, CA, USA). 
Next, the homogenate was incubated with 0.5 mg/ml of collagenase type IA and 20 µg/ml 
of type IV bovine pancreatic DNase (Sigma-Aldrich, St. Louis, MO, USA) for 20 min at 
37 °C in HBSS containing 5% FBS. After digestion, contaminating red blood cells were 
lysed by adding room temperature ACK lysing buffer (Thermo Fisher Scientific, 
Waltham, MA, USA) for 2 min. Cells were washed with PBS + 0.5% bovine serum 
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albumin (BSA, Thermo Fisher Scientific, Waltham, MA, USA) and subsequently passed 
through a 40 µm nylon cell strainer (Thermo Fisher Scientific, Waltham, MA, USA). 
Total cell numbers were determined using a Beckman Coulter Counter (Beckman Coulter 
Inc., Pasadena, CA, USA). To identify the different leukocyte populations in the lung, 
cells were first blocked with 2 µl TrueStain fcX (Biolegend, San Diego, CA, USA) for 5-
10 min on ice in a 96U-bottomed plate. Subsequently, cells were stained and incubated 
with their corresponding fluorochrome-conjugated antibody cocktails (Table 3.3) for 20 
min on ice in the dark. After three washing steps, cells were fixed with 2% formaldehyde 
(Sigma-Aldrich, St. Louis, MO, USA) and stored at 4 °C protected from light. Flow 
cytometry was performed using a FACS Calibur (BD Biosciences, Franklin Lakes, NJ, 
USA). Analysis of flow cytometry data was performed using Kaluza software (Beckman 
Coulter Inc., Pasadena, CA, USA). 
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Table 3.3: List of antibodies used for flow cytometry experiments. 
 
Cell type Cell surface marker Isotype Clone Supplier 
Alveolar 
Macrophages 
FITC anti-mouse CD11c. Armenian Hamster IgG N418 Biolegend 
PE anti-mouse Siglec-F. Rat IgG2a, k E50-2440 BD Biosciences 
APC anti-mouse I-A/I-E 
(MHC II). Rat IgG2b, k M5/114.15.2 Biolegend 
DCs 
FITC anti-mouse CD11c. Armenian Hamster IgG N418 Biolegend APC anti-mouse I-A/I-E 
(MHC II). Rat IgG2b, k M5/114.15.2 
Neutrophils 
FITC anti-mouse/human 
CD11b. Rat IgG2b, k M1/70 Biolegend APC anti-mouse Ly-
6G/Ly-6C (Gr-1). Rat IgG2b, k RB6-8C5. 
Eosinophils 
FITC anti-mouse CD11c. Armenian Hamster IgG N418 Biolegend 
PE anti-mouse Siglec-F. Rat IgG2a, k E50-2440 BD Biosciences 
APC anti-mouse CD45. Rat IgG2b, k 30-F11 Biolegend 
NK cells 
FITC anti-mouse CD3.  Rat IgG2b, k 17A2 
Biolegend APC anti-mouse CD335 
(NKp46). Rat IgG2a, k 29A1.4 
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3.8. Lung histology. 
 
The multi-lobed right lung was perfused with 10% neutral buffered formalin 
(NBF, VWR, Radnor, PA, USA) and collected on day 6 p.i. The dissected tissues were 
submerged in NBF and were allowed to shake for 2 days. Then, the lungs were 
transferred into cassettes and subsequently immersed in NBF. The perfused lungs were 
embedded in paraffin, sectioned into duplicate 5 µm sections, stained with hematoxylin 
and eosin (H & E), and scored in a blinded manner by a veterinary pathologist. Scores 
were given based on the presence, severity, and distribution of lesions in each lung lobe. 
Histopathological lesions were characterized by cellular infiltration and edema around 
blood vessels, bronchi and alveoli. A score of 0 denotes a normal lung, 1 indicates signs 
of mild perivascular edema, perivasculitis, and limited cellular infiltration within the 
pulmonary parenchyma, while a score of 2 denotes moderate perivascular edema, 
perivasculitis, and limited cellular infiltration within the pulmonary parenchyma. Finally, 
a score of 3 represents severe perivascular edema, perivasculitis, and limited cellular 
infiltration within the pulmonary parenchyma. 
 
3.9. Statistical analysis. 	  
GraphPad Prism 6 was used to analyze all the data (GraphPad Software, Inc., La 
Jolla, CA, USA). Differences among the groups as well as between time points were 
assessed using Student t-tests and the Newman-Keuls method for multiple comparisons. 
One-way ANOVAs were used to determine differences between the P-I-P/PVM and 
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PBS/PVM groups in flow cytometry experiments. Differences were considered 
significant at P<0.05.  
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4. RESULTS 
 
4.1. P-I-P mediates gene and protein expression of chemokines and cytokines involved in 
host’s innate immune responses. 
 
Mice were treated intranasally with P-I-P in order to monitor gene and protein 
expression profiles of cytokines and chemokines at 6, 24, 96 and 144 hr p.t. Highest 
mRNA expression was detected at 24 hr p.t. for CCL2, CCL3, CXCL2, and CXCL1 (Fig. 
4.1). For the IFN-γ-inducible protein 10, or CXCL10, the highest mRNA expression was 
observed as early as 6 hr p.t. It is important to note that there was a statistically 
significant decrease in chemokine mRNA levels between the 24- and 96-hr time points 
(p=0.0079 for CCL2, CXCL2, CXCL1 and CXCL10 and p=0.0317 for CCL3), although 
at the latest time-point assayed (i.e. 144 hr p.t.), chemokine mRNA levels were still 
upregulated compared to the PBS group. This change was expected, as these molecules 
tend to have short half-lives in vivo.  
In terms of pro-inflammatory cytokine gene expression profiles, P-I-P treatment 
induced moderate upregulation of TNF-α, IL-1β, IL-6 and IL-12β mRNA at 6 and 24 hr 
p.t. Subsequently, these levels decreased and remained constant with a median 
normalized fold-change under ~15-fold for most cytokines. TGF-β mRNA levels 
remained constant and were comparable to those in the PBS group. Interestingly, IL-10 
mRNA expression started with a moderate upregulation of less than 10-fold at 6, 24, and 
96 hr p.t., and then these levels further increased to approximately 34-fold at the 144 hr 
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time point. The unique profile of IL-10 mRNA can be attributed to its role in dampening 
immune responses in vivo. 
With regards to IFN-α/β and IFN-γ genes, highest mRNA expression was 
detected from 6 to 24 hr p.t., similar to the trends observed for the chemokine and 
cytokine genes. The highest level of IFN-α mRNA expression was at 24 hr p.t. Maximal 
IFN-β mRNA expression occurred earlier than that of IFN-α, at 6 hr p.t. ECs are the main 
constituent of the lung anatomy and are also a major source of IFN-β in the tissue. Thus, 
the fact that IFN-β mRNA levels were upregulated as early as 6 hr is not surprising. ECs 
are often considered the first line of defense of the lung and must respond to insults as 
early as it is physiologically possible. Additionally, ECs do not need to migrate from 
other body sites to exert their activity, which is in agreement with the earlier mRNA 
expression of this IFN. IFN-γ mRNA reached its peak at 6 hr p.t., with a median 
normalized fold-change of 58.65. By 24 hr p.t., the mRNA levels of this IFN strongly 
declined. Overall, these data suggest that P-I-P is a good inducer of the IFN response, and 
could generate an anti-viral state capable of protecting the animals from a lethal infection.  
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Figure 4.1: Heat map of chemokine and cytokine mRNA expression profiles in the 
single-lobed lungs of 5-6 week-old female Balb/c mice at 6, 24, 96 and 144 hr p.t. with 
either P-I-P or PBS. Each treatment group contained 20 mice in total, with sampling of 5 
animals at each time-point indicated above. All Ct values were normalized against the 
average of the β-actin levels of control animals for each specific time point indicated 
above. Normalized fold-change calculations were performed using the 2-ΔΔCt method. 
Data are shown as the median of five biological replicates.  
Normalized Fold-change 
Figure 1 
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In order to confirm and complement the results obtained from qPCR analysis, the 
total amount of chemokine, cytokine and IFN proteins in lung homogenate supernatants 
of mice treated with P-I-P was quantified. It is important to note that due to the nature of 
our samples, availability and sensitivity of the electrochemiluminescence multiplex 
ELISA kits, we were able to only measure selected chemokines, cytokines, and IFNs at 
the protein level. Similar to the mRNA expression data (Figs. 4.2A, 4.2C), CCL2 and 
CXCL1 proteins were highly expressed within the first 24 hr following P-I-P treatment, 
with concentrations between 3000-5000 pg/ml. At the 96-hr time point, the levels of 
these chemokine proteins decreased by approximately 86 to 88% with p= 0.0079 (400-
600 pg/ml) and during the last time point assayed, the protein concentration of CCL2 
increased to 920 pg/ml with p=0.0317 (Figs. 4.2B, 4.2D).  
The pro-inflammatory cytokine proteins TNF-α, IL-1β, and IL-6 had a slightly 
different trend than their mRNA (Figs. 4.2E, 4.2G, 4.2I). Highest protein concentrations 
were detected at 6 hr p.t., and at 24 hr p.t. These amounts decreased by 90%, 57% and 
82%, respectively, when compared to their previous values (p=0.0079). At 96 hr p.t., the 
levels of these cytokines continued to further decrease (p=0.0079). Notably, the decrease 
in protein concentration was most pronounced for IL-6, which went from 692 pg/ml to 
28.4 pg/ml within 72 hr. Similar to the chemokines, TNF-α, IL-1β, and IL-6 protein 
concentrations increased approximately 3-fold with p=0.0317 for TNF-α and p=0.0079 
for IL-1β, and IL-6 at the 144-hr time point (Figs. 4.2F, 4.2H, 4.2J).  
The IL-12 p70 protein concentration was 75 pg/ml at 6 hr after P-I-P treatment. 
During the next two time points (i.e. 24 and 96 hr p.t.), its quantity was significantly 
reduced by 38% and 90%, respectively (p=0.0079). At 144 hr, IL-12 p70 protein levels 
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remained constant (Fig. 4.2L). This trend is different from that of the mRNA (Fig. 4.2K) 
as in the latter we measured a subunit of the final heterodimer of IL-12 (i.e. p40 subunit), 
whereas in the former we measured total IL-12 as a heterodimer, or the combination of 
both p35 and p40 subunits (i.e. p70). The IL-10 protein concentrations were less than 5 
pg/ml during the first three time points following treatment, but at 144 hr p.t., there was a 
significant increase in protein expression, with a median concentration of 30.8 pg/ml 
(p=0.0079) (Fig. 4.2N). This pattern coincides with that observed at the mRNA level 
(Fig. 4.2M). Indeed, IL-10 is expressed at a later time point presumably because it 
dampens immune responses to prevent uncontrolled inflammation.  
IFN-γ showed a similar trend to that of the pro-inflammatory cytokines, with a 
starting concentration of 19.54 pg/ml, followed by a decrease of 85% (p=0.0079) at 24 hr 
p.t. During the last time point assayed, there was a 35-fold increase in IFN-γ protein level 
relative to the 96 hr time point (p=0.0079), resulting in a final concentration of 24.6 
pg/ml (Fig. 4.2P). This last event was similar to IL-10 protein expression, which was 
highest at 144 hr p.t.  
Collectively, we can conclude that the effect of P-I-P treatment is evident both at 
the mRNA and protein levels, with similar trends observed for both types of 
biomolecules. P-I-P-induced inflammation was short-lived, as both mRNA levels and 
protein concentrations were high within the first 24 hr following treatment, and then 
declined. While protein levels for chemokines and pro-inflammatory cytokines were 
slightly elevated at 144 hr p.t. compared to levels detected at the 96-hr time point, highest 
expression was detected between 6 to 24 hr p.t. It is likely that this minimal increase in 
protein concentration is not biologically significant. Only for IL-10 and IFN-γ, the 
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highest expression was measured at the latest time point (i.e. 144 hr p.t.), which suggests 
a different source of cells recruited by the P-I-P treatment.  
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Figure 4.2: Comparison between lung mRNA and protein expression levels of 
chemokine and cytokine genes at 6, 24, 96 and 144 hr p.t. Mice were given intranasal 
treatment of PBS or P-I-P and the single- and multi-lobed lungs of 5 mice per group per 
time point were collected separately for each individual animal at the time points 
indicated. Gene expression was assayed by qPCR, and protein expression by 
electrochemiluminescence-based multiplex ELISAs. Panels A, C, E, G, I, K, M, and O 
show mRNA expression for CCL2, CXCL1, TNF-α, IL-1β, IL-6, IL-12β (p40), IL-10, 
and IFN-γ, respectively. All Ct values were normalized against the average of the β-actin 
levels of control animals for each specific time point indicated above. Normalized fold-
change calculations were performed using the 2-ΔΔCt method. Two horizontal dotted lines 
at 0.5- and 2-fold were generated to indicate downregulation and upregulation, 
respectively. Panels B, D, F, H, J, L, N and P represent protein expression data in pg/mL 
for CCL2, CXCL1, TNF-α, IL-1β, IL-6, total IL-12 (p70), IL-10, and IFN-γ, respectively. 
Data are shown as individual values representing single animals as well as median with 
interquartile range of five biological replicates. Only statistically significant differences 
were indicated in the plots. * p<0.05 and ** p<0.01. 
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4.2. P-I-P protects adult Balb/c mice against a lethal PVM infection. 
 
Subsequently, we examined the efficacy of P-I-P pre-treatment at protecting Balb/c 
mice from lethal PVM challenge. We chose to deliver the treatment 24 hr prior to virus 
inoculation as during this time point, chemokine and cytokine mRNA and protein levels 
were high yet displaying a more balanced profile than that detected at 6 hr p.t. Figure 4.3 
illustrates the effects of P-I-P pre-treatment on weight loss, mortality, and clinical scores 
of mice lethally infected with PVM. Of note, animals treated with P-I-P 24 hr prior to 
virus challenge exhibited minimal weight loss, no overt signs of clinical disease, and 
100% survival by day 14 p.i. In regards to virus titers, P-I-P-treated animals had 
significantly lower numbers of viable virions as well as viral mRNA copies in their lungs 
when compared to the PBS-treated group (Figs. 4.4A, 4.4B). On day 14 p.i., lung 
homogenate supernatants of survivor mice were PCR-negative for PVM mRNA copy 
numbers, suggesting that P-I-P pre-treatment promotes the complete clearance of the 
virus in vivo. 
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Figure 4.3: Outline of trial, weight change, clinical and survival scores of P-I-P- or PBS-
treated Balb/c mice before and after intranasal PVM challenge. Mice were given 
intranasal treatment of PBS or P-I-P 24 hr prior to challenge with 3000 pfu PVM. 
Animals were weighed and scored before treatment (i.e. day -1), on the day of challenge 
(i.e. day 0), and for 14 days after infection. Panel A highlights the events occurring in the 
animal trial. Collection of lung tissue for virus titrations, cell influx and mRNA/protein 
expression studies was scheduled on days 0, 3 and 5 p.i. Lung samples for histopathology 
studies were collected on day 6 p.i. On day 14 p.i., qPCR was performed on survivor 
mice to determine their PVM status. Panel B illustrates weight loss of mice following P-
I-P treatment and PVM infection as a median percentage of the starting weight with error 
bars indicating the interquartile range. The stars indicate statistically significant 
differences between P-I-P/PVM and PBS/PVM groups. Panel C represents survival rates 
as the median percentage of the total number of animals per group during the 14 days 
following infection. Panels D and E show clinical scores for weight loss and appearance 
represented by the median value for each group throughout the entire animal trial. Each 
experiment was performed twice and all graphs illustrate the combined results of these 
two sets of experiments. The total number of animals equals to 10 per group, with an n = 
5 for each experiment. ** p<0.01. 
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Figure 4.4: PVM titers and absolute virus copy numbers in the lungs of P-I-P pre-treated 
Balb/c mice on days 0, 3 and 5 p.i. The multi-lobed lung was homogenized in DMEM 
and used for virus titrations.  Panel A shows the log of PVM titers in the lung tissue 
expressed in pfu/g. The single-lobed lung was processed in TRIzol and used for qPCR. 
Panel B shows the log of absolute PVM mRNA copy numbers, which were determined as 
described in the Materials and Methods section. Data are represented as the median with 
interquartile range of five biological replicates per group. Each experiment was 
performed twice. * p<0.05, ** p<0.01. 
A 
B 
Figure 4 
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4.3. P-I-P reduces lung lesions as well as influx of neutrophils and eosinophils into the 
lungs of Balb/c mice lethally infected with PVM. 
 
The lung pathology induced by PVM infection in P-I-P- and PBS-treated mice was 
examined in a subsequent trial. Treatment and challenge was delivered as previously 
described (Table 3.1) and lung sample collection was performed on day 6 p.i. A 
veterinary pathologist scored the lung sections in a blinded fashion based on severity of 
lesions, with 0 being normal and 3 being the worst outcome. The lung architecture of the 
control group (i.e. PBS/Medium) was normal with clear airways and alveoli, suggesting 
no signs of disease (Figs. 4.5A, 4.5B). The lungs of the P-I-P/PVM group showed signs 
of multifocal peribronchiolitis, perivasculitis and greater infiltration of leukocytes into 
the airways than the PBS/Medium control animals (Figs. 4.5C, 4.5D). Nonetheless, there 
were no signs of edema and hemorrhage in these mice.  As shown in figures 4.5E to 
4.5G, the PBS/PVM group had areas of acute to subacute alveolitis, multifocal to locally 
extensive, and severe perivasculitis with edema and hemorrhage in their lungs. Panels 
4.5F and 4.5G illustrate an enclosed region of edema of the lung. It can be noted that a 
large proportion of the infiltrating cells are polymorphonuclear leukocytes (PMNs) 
mostly in the form of neutrophil granulocytes. Edema was observed in all PBS-treated 
PVM-infected mice, whereas hemorrhage was only detected in 2 out of 5 mice. There 
was a statistically significant difference in lung pathology scores between P-I-P-treated 
and PBS-treated PVM-infected mice, suggesting that treatment with P-I-P reduces the 
amount and severity of lesions in the lungs following an otherwise lethal PVM infection 
(Fig. 4.5H).  
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Figure 4.5: Lung pathology of Balb/c mice pre-treated with P-I-P or PBS 24 hr prior to 
lethal intranasal PVM challenge. Four to five mice per group were treated as described in 
figure 3 and infected intranasally with 3000 pfu of PVM. All lung samples were collected 
on day 6 p.i. Panels A & B represent lung sections at 10X and 20X magnifications, 
respectively, for the PBS/Medium control group. Panels C & D show lung sections at 
10X and 20X magnifications, respectively of mice treated with P-I-P. Panels E to G 
illustrate lung sections of PBS-treated PVM-infected mice at 10X, 20X or 60X 
magnification, respectively. White arrows point to several areas of edema in the tissue, as 
well as PMNs within this region. Panel H shows the lung histopathology scores given on 
the basis of the severity and dissemination of the lesions visible in duplicate lung 
sections. Data are represented as both individual and median values for each group with 
error bars indicating the interquartile range. * p<0.05. 
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In view of the significant infiltration of PMNs into the lungs of PBS-treated 
PVM-infected mice, this phenomenon was further explored by measuring the influx of 
different innate immune cells into the lungs based on specific cell surface markers. The 
cells assayed were alveolar macrophages (CD11c+, MHCIIlow, SiglecF+), DCs (CD11c+, 
MHCIIhigh), neutrophils (CD11b+, Gr-1+), NK cells (CD3-, NKp46+) and eosinophils 
(CD45+, CD11c-, SiglecF+). P-I-P-treated mice showed increased numbers of alveolar 
macrophages on day 0 p.i., which peaked on day 3 p.i. By day 5 p.i., these values had 
leveled off and were comparable to those of both control and PBS-treated PVM-infected 
mice  (Fig. 4.6A). In terms of DCs, P-I-P treatment significantly increased the early 
migration of these cells into the lungs as compared to the PBS-treated PVM-infected 
animals. DC influx in P-I-P-treated mice increased over time and was significantly higher 
than the numbers detected in PBS-treated PVM-infected mice (Fig. 4.6B).  
Additionally, neutrophil infiltration in P-I-P-treated animals was characterized by 
an early transient recruitment into the lungs after PVM infection, and during later time 
points, these numbers tended to decrease and level off thereafter. In contrast, PBS-treated 
PVM-infected mice started with low neutrophil counts, and as the infection progressed, 
these values significantly increased over time (Fig. 4.6C). On day 5 p.i., PBS-treated 
PVM-infected mice had greatly elevated levels of neutrophils in the lungs, suggesting a 
possible neutrophilia, which was also confirmed and noted based on the histology shown 
in figures 4.5E to 4.5G. Eosinophil influx patterns of PBS-treated PVM-infected mice 
were similar to those of the neutrophils during days 3 and 5 after PVM challenge. 
Eosinophil numbers went up on day 3 p.i., and continued to significantly increase 
thereafter. However, P-I-P-treated animals display a pattern of eosinophil recruitment 
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similar to that of the PBS/Medium group. Thus, it is evident that PBS-treated PVM-
infected mice showed signs of eosinophilia, whereas P-I-P-treated animals did not (Fig. 
4.6D). Lastly, P-I-P treatment induced early recruitment of NK cells into the lungs on day 
0 p.i. By days 3 and 5 p.i., cell influx decreased, reaching numbers comparable to those in 
the PBS/Medium group. Interestingly, PBS-treated PVM-infected mice showed an 
opposite trend. These animals had delayed NK cell recruitment, with highest numbers on 
day 5 p.i. It is worth mentioning that at this time point, NK cell numbers were 
significantly higher in the PBS-treated PVM-infected mice compared to the P-I-P-treated 
group (Fig. 4.6E).  
Overall, P-I-P treatment induced early influx of cells that play key roles in the 
induction and regulation of antiviral innate immunity, such as NK cells, DCs, and 
alveolar macrophages. Additionally, P-I-P treatment reduced the excessive recruitment of 
cells associated with immunopathology, namely neutrophils and eosinophils, after PVM 
infection. 
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Figure 4.6: Infiltration of various immune cells into the lungs of P-I-P pre-treated Balb/c 
mice on days 0, 3 and 5 following lethal PVM challenge. Mice were given an intranasal 
treatment of PBS or P-I-P 24 hr prior to challenge with 3000 pfu PVM. The lungs of 3 
mice per group were collected, pooled, and processed at the time points indicated. 
Following physical and chemical digestion of the tissue, single-cell suspensions were 
acquired. Total numbers of alveolar macrophages (A), DCs (B), neutrophils (C), 
eosinophils (D), and NK cells (E) in the lungs were analyzed by flow cytometry. Results 
are presented as cell number x 104 per million cells. Data are shown as the median with 
interquartile range of three technical replicates per cell type assayed. Only statistically 
significant differences between P-I-P/PVM and PBS/PVM groups are indicated in the 
plots. * p<0.05, **p<0.01, *** p<0.001 and ****p<0.0001. 
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4.4. P-I-P pre-treatment promotes early upregulation of chemokines, pro-inflammatory 
cytokines and interferons, shifting the overall nature of immune responses against 
PVM. 
 
We examined the nature of the immune responses induced by P-I-P in terms of 
mRNA and protein expression levels of selected chemokines, cytokines and IFN 
molecules involved in PVM pathogenesis. As shown in the heat map presented in figure 
4.7, P-I-P-treated mice showed an early upregulation of CCL2, CCL3, CXCL2, CXCL1, 
and CXCL10 mRNA levels on day 0 p.i. compared to the PBS-treated animals. The 
normalized fold-change of chemokine mRNAs ranged from 4.45 to 100.08 on day 0 p.i. 
During the next two time points following PVM infection, CCL3, CXCL2 and CXCL1 
mRNA expression remained fairly stable and did not change over time. CCL2 and 
CXCL10 mRNA levels decreased on day 3 (p=0.0079) followed by an increase on day 5 
(p=0.0317 for CCL2 and p=0.0159 for CXCL10).  In addition to mRNA, protein levels of 
CCL2 and CXCL1 were measured in lung homogenate samples. In both P-I-P- and PBS-
treated groups, CCL2 and CXCL1 mRNA and protein levels followed a very similar 
pattern (Figs. 4.8A to 4.8D). PBS-treated mice expressed increasing amounts of these two 
chemokines over time (p=0.0079). The gradual changes in mRNA levels started with a 
19- and 29-fold increase on day 3 p.i. for CCL2 and CXCL1, respectively, escalating to a 
further 17-fold increase for CCL2 and 2-fold increase for CXCL1 on day 5 p.i. In these 
mice the CCL2 and CXCL1 protein amounts increased dramatically, from 58.2 and 94.0 
pg/ml on day 0 p.i. to the staggering amounts of 15,278 and 5,244 pg/ml on day 5 p.i., 
respectively. In contrast, P-I-P-treated mice not only started with early upregulated 
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mRNA levels on day 0 p.i., but this expression also remained stable over time being 
significantly lower than the amounts detected in their PBS-treated animals on day 5 p.i. 
(Figs. 4.8A, 4.8C). CCL2 and CXCL1 protein concentrations were ~36-fold higher in 
these mice than in the PBS-treated group on day 0 p.i., On day 5 p.i., CCL2 and CXCL1 
protein levels in P-I-P treated animals were 92% and 78% lower than those detected in 
the PBS-treated group (Figs. 4.8B, 4.8D).  
In terms of cytokine molecules, on day 0 p.i., TNF-α, IL-1β, IL-6, IL-12 and IL-
10 mRNA were slightly upregulated in the P-I-P-treated group, with highest normalized 
fold-change of 12.36. On days 3 and 5 p.i., these animals had relatively stable mRNA 
levels, with normalized-fold changes under 10-fold for most genes (Fig. 4.7). IL-10 was 
the exception, as on day 5 p.i. mRNA levels were much higher than any other value 
observed in this group. In the case of TGF-β, mRNA levels did not change over time and 
were similar to those of the reference gene in both PBS- and P-I-P-treated animals. 
Regarding the PBS-treated group, the cytokines followed the same trend as the 
chemokines, characterized by increasing mRNA levels overtime and highest expression 
on day 5 p.i. This applied to all molecules including IL-10.  
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Figure 4.7: Heat map of chemokine and cytokine mRNA expression profiles of 5-6 
week-old P-I-P- or PBS-treated Balb/c mice before and after intranasal PVM challenge. 
Mice were given an intranasal treatment of PBS or P-I-P 24 hr before challenge with 
3000 pfu PVM. The single-lobed lungs of 5 mice per group per time point were collected 
on days 0, 3 and 5 p.i. All Ct values were normalized against the average of the β-actin 
levels of control animals for each specific time point indicated above. Normalized fold-
change calculations were performed using the 2-ΔΔCt method. Data are shown as the 
median of five biological replicates. 
Normalized Fold-change 
Figure 7 
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Protein expression trends for TNF-α and IL-6 were similar to their mRNA trends 
for both P-I-P-and PBS-treated groups (Figs. 4.8F, 4.8J). P-I-P-treated animals displayed 
10- and 35-fold higher concentrations of TNF-α and IL-6 proteins, respectively, on day 0 
when compared to PBS-treated mice. TNF-α protein concentrations remained relatively 
constant overtime and IL-6 protein levels decreased by 94% on day 3 p.i. (p=0.0159). In 
contrast, PBS-treated mice had elevated TNF-α and IL-6 protein concentrations on day 5 
p.i., which were 57- and 83-fold higher than values in the P-I-P-treated group, 
respectively. The remaining cytokines assayed displayed a different trend. Although both 
IL-1β mRNA and protein levels were relatively low in PBS-treated mice, IL-1β mRNA 
levels remained stable between days 0 and 3 p.i. and protein levels began to rise 
significantly after day 0 p.i. (p=0.0079). P-I-P-treated mice displayed the characteristic 
early expression of mRNA and protein, which was followed by a constant maintenance of 
IL-1β levels throughout the 5 days of infection (Figs. 4.8G, 4.8H). The IL-12 p70 protein 
concentration in PBS-treated mice started to rise between days 3 and 5 p.i. and was 
significantly higher by day 5 after infection (p=0.0079). P-I-P-treated mice had 3X the 
concentration of IL-12 p70 in PBS-treated animals on day 0 p.i. By day 5 p.i., the former 
mice had a 92% lower concentration of IL-12 p70 than that measured in the latter group 
(Figs. 4.8K, 4.8L). Lastly, in PBS-treated mice, IL-10 mRNA levels increased 
significantly over time (p=0.0079), with highest expression on day 5 p.i. The protein 
concentrations in the lungs began to rise on day 3 p.i., and became significantly higher by 
day 5 p.i. (p=0.0079). In P-I-P-treated mice, mRNA and protein levels started with an 
early upregulation on day 0 p.i., remained constant till day 3 p.i., and then increased by 
day 5 after PVM infection (p=0.0079).  Overall, by day 5 p.i., the levels of most cytokine 
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molecules in the P-I-P-treated group were significantly lower than those of the PBS-
treated group. The exceptions to this trend were IL-1β and IL-10, where protein levels 
were not significantly different from those of the PBS-treated group.  
In terms of the IFN response, P-I-P-treated animals displayed an earlier expression of 
type I IFN mRNA compared to PBS-treated mice (Fig. 4.7). By day 3 p.i., these mice 
experienced a significant drop in IFN-α and IFN-β mRNA levels (p=0.0079), which then 
remained constant between days 3 and 5 p.i. In contrast, the PBS-treated animals showed 
increased expression of type I IFNs throughout the infection. Both IFN-γ mRNA and 
protein expression were elevated on day 0 in P-I-P-treated mice and were significantly 
higher than those of the PBS-treated animals (Figs. 4.7, 4.8O, and 4.8P). The PBS-treated 
mice produced increasing amounts of IFN-γ throughout the infection, especially on day 5 
p.i., when both IFN-γ mRNA and protein levels were higher than those in the P-I-P-
treated animals (Figs. 4.8O, 4.8P). Overall, these data suggest that P-I-P acts as an 
immunomodulator capable of preventing chemokine and cytokine molecules from 
reaching exacerbated levels in the lungs during lethal PVM infection. 
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Figure 4.8: Comparison between lung mRNA and protein expression levels of 
chemokine and cytokine genes of P-I-P pre-treated Balb/c mice. Mice were given an 
intranasal treatment of PBS or P-I-P 24 hr before challenge with 3000 pfu PVM. The 
single- and multi-lobed lungs of 5 mice per group per time point were collected 
separately for each individual animal on days 0, 3 and 5 p.i. Gene expression was assayed 
by qPCR, and protein expression by electrochemiluminescence-based multiplex ELISAs. 
Panels A, C, E, G, I, K, M, and O represent mRNA expression of CCL2, CXCL1, TNF-α, 
IL-1β, IL-6, IL-12β (p40), IL-10, and IFN-γ, respectively. All Ct values were normalized 
against the average of the β-actin levels of control animals for each specific time point 
indicated above.  Normalized fold-change calculations were performed using the 2-ΔΔCt 
method. Two horizontal dotted lines at 0.5- and 2-fold were generated to indicate 
downregulation and upregulation respectively. Panels B, D, F, H, J, L, N and P represent 
protein expression data in pg/mL for CCL2, CXCL1, TNF-α, IL-1β, IL-6, total IL-12 
(p70), IL-10, and IFN-γ, respectively. Data are shown as individual values representing 
single animals as well as median with interquartile range of five biological replicates. 
Only statistically significant differences are indicated in the plots. *p<0.05 and **p<0.01. 
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4.5.Weight loss and mortality increases when P-I-P treatment is delivered at earlier time 
points prior to infection. 	  
With a better understanding of P-I-P’s mechanism of action in terms of innate 
immunity, we decided to further investigate the duration of protection that P-I-P is 
capable of conferring to mice from lethal PVM challenge. For these experiments, we 
followed the same protocols as before, but instead of delivering the treatment 24 hr prior 
to challenge, we treated mice with P-I-P at 3, 4, 5 or 6 days prior to PVM infection. 
Weights and clinical signs were monitored throughout the entire trial, including the days 
following treatment. In certain experiments we collected lungs of survivor mice on day 
14 p.i. to measure PVM copy numbers and determine if these mice were PVM-negative 
using qPCR. Animals treated 3 days prior to infection experienced weight loss of less 
than 10% and survival of 90% (Figs. 4.9A, 4.9B). Also, these mice had low scores for 
weight loss and appearance (Figs. 4.10A, 4.10B). When P-I-P treatment was delivered 4 
days prior to challenge, mice had a further increase in weight loss (i.e. between 10-12%) 
and a survival rate of 60% (Figs. 4.9C, 4.9D). Clinical scores for weight changes and 
appearance also increased slightly (Figs. 4.10C, 4.10D). Mice that received P-I-P 
treatment on day -5 had a weight loss greater than 15%, a survival rate of 50% (Figs. 
4.9E, 4.9F) and more severe clinical signs (Figs. 4.10E, 4.9F). Lastly, mice with P-I-P 
treatment delivered on day -6 showed weight loss of 20% and survival of 30% (Figs. 
4.9G, 4.9H). Clinical scores were higher, both weight loss and appearance with highest 
scores of 2 (Figs. 4.10G, 4.10H). This trend suggests that treatment efficacy is reduced 
the earlier the treatment is delivered, leading to a poorer performance at providing 
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protection against severe PVM disease. We noted that P-I-P still had good activity up to 3 
days prior to infection. However, when administered on day -4 or earlier, the effect of P-
I-P started to lose potency resulting in less favorable clinical outcomes overall. 
Regardless of the setting and day of the treatment, survivor mice of the day -3 and -6 
trials were PVM-negative on day 14 p.i., suggesting that P-I-P pre-treatment is able to 
mediate complete clearance of PVM from the lungs of survivors.	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Figure 4.9: Percent weight loss and survival scores of Balb/c mice treated with P-I-P or 
PBS 3, 4, 5 and 6 days prior to intranasal PVM challenge. Mice were given prophylactic 
intranasal treatment of PBS or P-I-P at the time points indicated above, followed by a 
3000 pfu PVM challenge. Animals were weighed and scored daily after treatment and for 
14 days following infection. Panels A, C, E, and G show weight loss of mice treated 3, 4, 
5 and 6 days prior to PVM infection, respectively, expressed as the median percentage of 
the starting weight with error bars indicating the interquartile range. Panels B, D, F and H 
illustrate percent survival of mice treated 3, 4, 5 and 6 days prior to infection, 
respectively, expressed as the median percentage of the total number of animals per 
group during the 14 days following infection. Each experiment was performed twice and 
all graphs illustrate the combined results of these two experiments. The total number of 
animals equals to 10 per group, with an n = 5 for each experiment. 	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Figure 10 
0 = Normal weight. 
1 = Weight loss of 4 to 10.9% 
2 = Weight loss of 11 to 19.9% 
3 = Weight loss > 20% 
A B 
0 = Normal. 
1 = Lack of grooming. 
2 = Pilo erection, rough coat, 
ocular/nasal discharge. 
3 = Very rough coat, abnormal 
posture, enlarged pupils. 
0 = Normal weight. 
1 = Weight loss of 4 to 10.9% 
2 = Weight loss of 11 to 19.9% 
3 = Weight loss > 20% 
C D 
0 = Normal. 
1 = Lack of grooming. 
2 = Pilo erection, rough coat, 
ocular/nasal discharge. 
3 = Very rough coat, abnormal 
posture, enlarged pupils. 
0 = Normal weight. 
1 = Weight loss of 4 to 10.9% 
2 = Weight loss of 11 to 19.9% 
3 = Weight loss > 20% 
E 
0 = Normal. 
1 = Lack of grooming. 
2 = Pilo erection, rough coat, 
ocular/nasal discharge. 
3 = Very rough coat, abnormal 
posture, enlarged pupils. 
F 
0 = Normal weight. 
1 = Weight loss of 4 to 10.9% 
2 = Weight loss of 11 to 19.9% 
3 = Weight loss > 20% 
G 
0 = Normal. 
1 = Lack of grooming. 
2 = Pilo erection, rough coat, 
ocular/nasal discharge. 
3 = Very rough coat, abnormal 
posture, enlarged pupils. 
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Figure 4.10: Clinical scores of Balb/c mice treated with P-I-P or PBS 3, 4, 5 and 6 days 
prior to intranasal PVM challenge. Mice were given prophylactic intranasal treatment of 
PBS or P-I-P on the time points indicated above, followed by a 3000 pfu PVM challenge. 
Animals were weighed and scored daily after treatment and for 14 days following 
infection. Panels A, C, E and G represent clinical score for weight loss and panels B, D, F 
and H illustrate clinical scores for changes in appearance of mice treated 3, 4, 5 and 6 
days prior to lethal PVM infection, respectively. Data are presented as the median value 
for each group during the entirety of the animal trial. Each experiment was performed 
twice and all graphs illustrate the combined results of the two sets of experiments. The 
total number of animals equals to 10 per group, with an n = 5 for each experiment.	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5. DISCUSSION AND CONCLUSIONS 
 
5.1. Immunomodulators in the context of microbial infections. 
 
Most immunomodulatory regimes for infectious diseases have two major goals: 
enhance pathogen clearance and suppress undesirable immune responses. Examples of 
these can be found in the context of both bacterial and viral infections. IFN-γ in 
conjunction with gentamicin or vancomycin is effective at reducing morbidity and 
mortality against drug-resistant Enterococcus faecalis in mice [122]. Administration of 
CpG ODN protects specific-pathogen-free mice against Listeria monocytogenes and 
Francisella tularensis [123]. Similarly, treatment with various immunomodulators for 
prophylaxis has been previously performed in both influenza and Severe Acute 
Respiratory Syndrome coronavirus (SARS-CoV) infection models [108, 124]. With 
regards to PVM as well as RSV, an effective therapeutic approach should be both 
antiviral and immunomodulatory in nature [12, 125]. One group demonstrated this 
principle for PVM by injecting mice with ribavirin together with CCL3 blockade by 
either gene-deletion or antibody [125]. The overall conclusion of their study was that it is 
in fact required to have both antiviral and immunomodulatory components in a treatment 
regimen against PVM. The group found that in order to achieve the desired outcomes, 
two daily doses of ribavirin and a single daily dose of anti-CCL3 antibody were required 
during a period of 12 days [125]. As mentioned in the introduction, ribavirin is known to 
induce toxicity and severe side effects in pediatric patients, discouraging its use in these 
populations. A few advantages of P-I-P treatment include the fact that it indirectly 
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induces moderate antiviral activity and also possess the ability to down-modulate levels 
of chemokines like CCL3 during PVM infection. This was also the case for other 
biological mediators of disease pathogenesis such as CCL2, involved in monocyte 
recruitment, CXCL1, key mediator of neutrophil chemotaxis, as well as TNF-α and IL-6, 
which induce vascular permeability and activation of high endothelial venules. If 
delivered 24 hr prior to PVM infection, P-I-P leads to the effective clearance of the virus, 
in conjunction with excellent survival rates, minimal clinical disease and no short-term 
observable side effects.  
 
5.2. The importance of well-regulated innate immune responses in the control of viral 
respiratory infections.  
 
Alveolar macrophages are pivotal patrollers of the lung milieu whose major role 
is to maintain homeostasis within this tissue [126, 127]. In the context of respiratory viral 
infections, it has been reported that alveolar macrophages, in conjunction to pDCs, are 
key mediators of viral clearance and disease resolution in vivo [128, 129]. One group has 
recently shown that depletion of alveolar macrophages by intranasal administration of 
dichloromethylene bisphosphonate liposomes prior to RSV infection resulted in increased 
virus titers in the lungs, exacerbated disease and lung inflammation within the tissue 
[129]. P-I-P treatment is associated with enhanced viral clearance, reduced 
immunopathology as well as higher alveolar macrophage numbers in the lungs during 
lethal PVM infection. It is likely that the latter event provided P-I-P-treated mice with a 
	   85 
clear advantage, as alveolar macrophages are known to dampen excess inflammatory 
responses within the lung microenvironment [130]. 
As reviewed by Gabelloni et al., it is suggested that neutrophils may play an 
important role in the regulation of local immunity, as these cells secrete a multitude of 
molecules that modify immune responses [131]. One study showed that uncontrolled 
influx of neutrophils during an active influenza infection leads to severe lung 
inflammation [132, 133]. Similarly, prominent granulocyte accumulation in the lungs is a 
hallmark of PVM infection, which eventually progresses to pulmonary edema and 
respiratory distress [134]. In contrast, one group showed that mice depleted of neutrophils 
before the establishment of influenza A virus infection developed increased morbidity 
and mortality [128, 133]. This evidence suggests that neutrophil infiltration does not 
always lead to detrimental outcomes as it was once thought to do. Interestingly, early 
neutrophil influx was detected in P-I-P-treated mice. While it is possible that the 
treatment itself is able to mediate moderate neutrophil recruitment into the lungs by the 
production of chemo-attractants like CXCL1 and CXCL2, these mice did not show signs 
of neutrophilia. Instead, these animals had low neutrophil counts that were maintained at 
stable levels throughout the days following treatment and infection. Our results are in 
agreement with the concept that neutrophils are likely to participate in the effective 
control and clearance of viral pathogens, if and only if these are adequately recruited and 
regulated within the tissue in a manner that prevents immunopathology from occurring. 
Previously, as well as in the current study, we and others showed that NK cell 
recruitment takes place at later time points during PVM infection [13, 135], which is 
correlated to an increase in lung virus titers, suggesting that the NK cell recruitment 
	   86 
occurs too late to be beneficial. It is likely that P-I-P pre-treatment has a direct effect on 
NK cell biology. P-I-P induced the production of chemokines involved in NK cell 
recruitment, namely CCL2, CCL3 and CXCL10. Thus, this cell population infiltrated the 
lungs much earlier than it normally would during a natural PVM infection. In addition, P-
I-P pre-treatment induced the production of cytokines involved in NK cell activation, 
such as IFN-β and IL-12. Therefore, it is possible to assume that P-I-P-treated mice have 
an effective local antiviral innate immune response prior to the establishment of an active 
PVM infection within the airways of these animals.   
Type I IFN mRNA was upregulated shortly after P-I-P intranasal delivery. If 
these molecules are present in the lungs prior to infection, they can promote an antiviral 
state required to limit virus replication in both infected and bystander cells [136]. Perhaps 
this is another mechanism contributing to the reduction in PVM titers observed on days 3 
and 5 p.i.  
 
5.3. Advantages of P-I-P as an alternative approach to treat RSV infections in susceptible 
populations. 
 
The attractiveness of P-I-P as an immunomodulator is due to the complementary 
properties of its individual constituents. Poly I:C is a PRR ligand with 
immunostimulatory activity, especially in applications involving cancer 
immunotherapies, and more recently in treatment against infectious diseases and as 
vaccine adjuvants [102, 108, 137]. Poly I:C signals through PRRs such as TLR3, RIG-I 
and MDA-5. It induces the production of pro-inflammatory cytokines, chemokines and 
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type I IFNs. The latter is of great importance as most paramyxoviruses inhibit IFN-α/β 
through the NS1/NS2 proteins [13]. However, as mentioned previously, too much 
stimulation of local immune responses can result in detrimental effects to the organ 
system in question, in this case the respiratory tract. Due to the nature of poly I:C and its 
downstream signaling cascade, it has the potential to exacerbate RSV-induced pro-
inflammation due to the possible amplification of the NF-κB pathway. We believe that P-
I-P has an advantage over poly I:C therapies as it is more modulatory in nature. This 
property in fact would benefit individuals at risk of RSV infection because it ensures 
optimal regulation of immune responses in the context of an active infection. Innate 
defense regulator peptides are able to modulate immune responses in vivo by reducing 
levels of pro-inflammatory mediators, modulate the expression of host defense genes 
within macrophages and other immune cells, and are able to selectively recruit innate 
immune cells into the site of infection [113]. Most studies involving IDR peptides as 
immunomodulators focus on bacterial pathogens [113]. We believe that IDR peptide 
1002 is one of the major anti-inflammatory components in our formulation as it has been 
previously shown that other peptides of its kind are able to selectively suppress 
downstream signaling events in response to different TLR agonists [113]. Lastly, PCEP is 
a polyphosphazene of synthetic origin known for its immunoadjuvant activity and as a 
delivery vehicle. This is the first study of its kind using PCEP in an immunomodulatory 
treatment formulation rather than as an adjuvant.  
We propose that P-I-P can be used prophylactically for the prevention of RSV 
infections in high-risk populations like young children and the elderly. These populations 
possess immune systems that do not perform optimally, due either to immune immaturity 
	   88 
or senescence. Thus, it is quite logical to use immunostimulatory compounds to enhance 
host immune responses to combat viral infections. Furthermore, P-I-P as an 
immunotherapy against RSV would be more cost-effective than monoclonal antibody, 
which is currently used as prophylaxis in high-risk infants. Up to 3 days prior to 
exposure, P-I-P protected approximately 90% of the animals. If P-I-P were to be taken 
regularly, for instance every 3 days, one might maintain a longer protective state in the 
respiratory tract. The local and systemic effects of taking a steady P-I-P regimen are yet 
to be elucidated. This concept is particularly attractive for the elderly. Taking into 
consideration that RSV infections are most predominant in fall and winter seasons, 
elderly patients inhabiting nursing homes could be treated with the P-I-P formulation 
during outbreaks of RSV or possibly other respiratory infections such that partial immune 
protection can be provided. The lack of antigen in our formulation suggests that P-I-P 
acts primarily at the level of the innate immune system of the host. This fact allows us to 
speculate on the possibility of a well-established P-I-P therapy to protect patients from 
multiple viral infections at once. It would be beneficial if one can protect the most 
vulnerable populations from major diseases like influenza, CoV, and RSV infections as 
most of these tend to be transmitted through the same route of exposure and during the 
same seasons. However, studies confirming such pleiotropic effect are yet to be 
performed.   
We used a lethal dose of PVM in all our animal studies as a disease model in 
order to provide a proof of concept for the effectiveness of P-I-P. In the context of RSV 
infections, it is unlikely that one would be naturally exposed to such doses of virus 
inoculum. When used in a real-life scenario, as a treatment against RSV, P-I-P 
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prophylaxis might last much longer than what we reported using the PVM disease model. 
If the viral challenge dose were reduced, we would probably obtain more survivors as a 
result of P-I-P administration at earlier time points before PVM challenge. The downside 
of such an approach is that it would be unclear if any reduction in virus replication and 
disease were due to the direct effect of P-I-P or the sub-lethal nature of the challenge 
itself. Nonetheless, studies involving a lower virus challenge might be required as these 
are likely to complement the existing data with information regarding the nature of both 
innate and adaptive immune responses during a full course of PVM infection. In this way, 
we would be able to mimic a more realistic setting of infection resulting in a better 
understanding of the potential effects of P-I-P in humans. 
 
5.4. General conclusions and future directions. 	  
In the present study we assessed the potential of a novel immunomodulatory 
treatment, P-I-P, in a PVM disease model as an alternative approach to treat severe 
respiratory infections. A single dose of P-I-P significantly upregulated the expression of 
genes involved in host defense as early as 6 hr p.t. Most cytokines and chemokines 
remained at fairly high levels from 6 to 24 hr p.t. Thereafter, these levels decreased as 
expected due to their relatively short half-lives. These data suggested that 24 hr prior to 
challenge would be an ideal starting time point for the initial delivery of P-I-P as a 
treatment against lethal PVM disease. Treatment at 24 hr prior to PVM challenge reduced 
weight loss, clinical symptoms and lung immunopathology, and conferred complete 
survival. P-I-P displayed genuine immunomodulating potential as it stimulated early 
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expression of key chemokines and cytokines involved in PVM pathogenesis and host 
defense; it also downregulated the levels of such factors during the first 5 days following 
PVM infection. It is important to highlight the fact that P-I-P did not cause any short-term 
observable adverse effects as evidenced by the absence of clinical signs following 
treatment. Another important feature of P-I-P immunomodulation is the substantial 
reduction of neutrophil and eosinophil influx during infection. Interestingly, P-I-P 
mediated early recruitment of NK cells and DCs into the lungs. Influx of alveolar 
macrophages was also increased, but its peak took place on day 3 p.i. Lastly, the 
protective effect of P-I-P was maintained if delivered as early as 3 days prior to lethal 
challenge. It is worth mentioning that survivor mice were deemed PVM-free on day 14 
p.i. This suggests that P-I-P modulation of host immune responses is able to trigger 
complete clearance of the virus from the site of infection.  
As mentioned previously, the flexible nature of P-I-P as an immunomodulator 
allows for its potential use as an immunotherapy against other infectious diseases. We 
would like to try this approach against other infectious agents, starting with other 
respiratory viruses, moving to bacterial respiratory diseases, and so on.  In order to do 
this, a thorough understanding of its mechanism of action is required. We believe that P-
I-P prophylaxis can condition the respiratory tract of the animals with a controlled 
inflammatory innate immune response. This, in turn, would alter the virus life cycle, 
preventing it from thriving and causing a dysfunctional and exacerbated inflammatory 
syndrome. For future studies, it would be very interesting to use knockout mice or 
perform immune cell depletions in vivo, as it is likely that both cellular and soluble 
factors play a major role in the mechanism of protection mediated by P-I-P. It may be of 
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interest to investigate the role of early recruited neutrophils in P-I-P treated mice by 
administering antibodies intravenously to deplete these granulocytes temporarily. In this 
way, it could provide us with important evidence regarding the direct contribution of 
neutrophils into the main mechanism of action of our formulation. Additionally, other 
studies should focus on cells that promote antiviral immunity in the airways such as NK 
cells, alveolar macrophages, interstitial macrophages and pDCs. Monocyte infiltration 
into the lungs was not investigated in detail during this study, but based on the overall 
chemokine profile detected during P-I-P treatment and PVM infection, we can speculate 
that monocytes are certainly being recruited into the site of infection (i.e. high expression 
of CCL2). It would be worthwhile to study this cell population as monocytes may 
directly contribute to viral clearance within the tissue as well as the development of 
immunopathology [138]. Stat1-/- or Ifnar-/- gene knockout experiments could be 
performed to validate the direct contribution of P-I-P-induced IFNs in mediating 
protection against lethal PVM disease in vivo. A common feature of many RSV surrogate 
animal models is the fact that age seems to have a direct influence in disease 
susceptibility. Thus, it would be worthwhile to study the protective effects of P-I-P in 
different age groups (i.e. neonates, elderly). Lastly, we would like to explore P-I-P as a 
therapeutic agent by adjusting the relative dose of P-I-P and its individual constituents as 
well as the number of intranasal treatments needed that is most suitable for such an 
application. In that way, we can propose an optimum treatment course that is suitable for 
different types of respiratory disease severities and susceptibilities. 
 
(Manuscript to be submitted to Antiviral Research.) 
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